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ABSTRACT 
 
Angiogenesis by either normal or neoplastic cells involves a delicate 
balance of both angiogenic and angiostatic regulators.  In the ovary, normal 
physiological angiogenesis occurs around the developing follicle and corpus 
luteum in response to hormonal shifts.  Interestingly, carcinomas arising from the 
ovary are usually highly vascularized and are commonly clinically observed to 
produce cyst fluids or ascites which contain both angiostatic and/or angiogenic 
regulators.  However, in contrast to normal angiogenesis, angiogenesis 
associated with epithelial ovarian cancer usually produces aberrant vasculature 
that may promote neoplastic progression.   Therefore, the ovary and ovarian 
cancers provide models to study the mechanisms governing the strict balance of 
angioregulators in both normal and tumor angiogenesis.  While most studies to 
date have focused on angiogenic regulators for normal and aberrant 
angiogenesis, we investigated the potential for dysregulation of angiostatic 
regulators to contribute to the etiology of epithelial ovarian cancer.  Therefore, in 
this study, we examined two angiostatic regulators, angiostatin and semaphorin 
3F, in epithelial ovarian cancer. 
Angiostatin, a cleavage product of the circulating zymogen plasminogen, 
was isolated from serum and urine of mice bearing a Lewis lung carcinoma and 
xii 
in vivo studies have demonstrated its potent angiostatic properties.  Thus, we 
investigated the potential prognostic/diagnostic advantage of aberrant angiostatin 
expression with epithelial ovarian cancer.  We found that urinary angiostatin, 
compared to other angioregulators in plasma or urine, could serve as an effective 
biomarker for early detection of epithelial ovarian cancer, especially when used in 
combination with cancer antigen 125.  Additionally, urinary angiostatin correlated 
with both recurrent disease as well as successful tumor ablation further 
supporting its potential as a disease biomarker. 
Alternative biological functions for the axon guidance molecule, 
semaphorin 3F, have been reported particularly in regard to angiogenesis, tumor 
progression and metastasis.  However, the underlying mechanisms governing 
semaphorin 3F regulation and dysregulation remain unclear.  Therefore, we first 
investigated the clinical relationship between semaphorin 3F expression and 
epithelial ovarian cancer progression.  These immunohistological studies 
revealed that, similar to lung cancer, semaphorin 3F expression decreased with 
progression supporting a tumor suppressor-like role for semaphorin 3F.  
Additionally, we found that calcium, an essential cellular signaling molecule, 
could mediate transcriptional suppression of semaphorin 3F expression in a 
CREB-dependent manner. 
Lastly, given the antagonistic relationship between semaphorin 3F and 
vascular endothelial growth factor, we sought to determine whether semaphorin 
3F and vascular endothelial growth factor promoted opposing effects on a 
common downstream target.  In the course of these studies we determined that 
xiii 
telomerase is a novel molecular target of semaphorin 3F in ovarian cancer cells 
such that semaphorin 3F suppresses telomerase activity while vascular 
endothelial growth factor promotes telomerase activity.  In addition, we found that 
the inverse relationship between semaphorin 3F and telomerase was mediated 
through transcriptional inhibition of the hTERT promoter by semaphorin 3F. 
In conclusion, this research shows that dysregulation of the angiostatic 
regulators, angiostatin and semaphorin 3F, may contribute to the etiology of 
epithelial ovarian cancer.  In the future, dysregulation of these and other 
angiostatic regulators may be exploited for therapeutic intervention or as 
biomarkers for early detection which would allow women more treatment choices 
and hopefully, reduce the mortality associated with this insidious disease.      
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CHAPTER I 
INTRODUCTION 
 
Ovarian Cancer 
 
 Ovarian cancer is the most lethal gynecologic malignancy and is neither a 
common nor rare disease.  The American Cancer Society estimates 
approximately 22,000 new cases of ovarian cancer in the United States in 2010 
and over half, approximately 14,000, of these women will succumb to the disease 
(1).  Over the past two decades advances in both cytoreductive surgery and 
combination chemotherapy have contributed to a modest increased overall 5-
year survival.  Furthermore, when cancer is confined to the ovaries, stage I, up to 
90% of patients can be cured with currently available therapy.  Unfortunately, due 
to a lack of early symptoms and no reliable screening method, ovarian cancer 
remains a “silent” killer, with 70% of women diagnosed at an advanced stage.  
Therefore, ovarian cancer represents a great clinical challenge in gynecologic 
oncology. 
2 
Epidemiology 
The incidence of ovarian cancer is highest in the U.S. and Europe and 
lowest in developing countries (2).  Although the gap is narrowing, in the U.S., 
there is a higher frequency of ovarian cancer among Caucasian women rather 
than African-American or Asian-American women (2).  Ovarian cancer is more 
prevalent among perimenopausal and postmenopausal women, generally 
occurring after the age of 40 (3).  The majority of ovarian cancers are sporadic, 
whereas the occurrence of hereditary ovarian cancer accounts for only a small 
proportion (5-10%) of total cases; however, family history of disease is the most 
significant risk factor for ovarian cancer.  Advances in molecular genetics have 
identified specific germline mutations in the breast cancer 1 and 2 genes 
(BRCA1, BRCA2) and women who harbor these alterations carry an increased 
susceptibility to both ovarian and breast cancer (4).  Additional risk factors 
include early menarche, late menopause, nulliparity, estrogen,  infertility, fertility 
drugs, obesity, and use of talc as well as other environmental factors (3).  
Conversely, numerous studies have identified protective factors for risk of 
ovarian cancer.  These include use of oral contraceptives, multi-parity, tubal 
ligation, and history of breastfeeding (5-7).   
 
Histopathology 
More than 90% of ovarian cancers have been traditionally thought to arise 
from the simple ovarian surface epithelium (OSE) which covers the ovary (Figure 
1).  This dynamic epithelium remains in a relatively uncommitted state with 
3 
mesenchymal features and a propensity to undergo epithelial-mesenchymal 
transition (3, 8).  As a result, in contrast to other epithelial malignancies, ovarian 
cancers tend to be more differentiated than their tissue of origin and present as 
morphological derivatives of coelomic epithelium of the fallopian tube, endocervix 
and endometrium (8).  The predominant form of epithelial ovarian cancer (EOC) 
is denoted as serous which resembles tubal epithelium, followed by mucinous 
and endometriod which resemble endocervical and endometrial epithelium, 
respectively (7).  Less common epithelial histologic subtypes of ovarian cancer 
include clear cell, Brenner, small cell, and undifferentiated carcinoma.  Additional 
non-epithelial types of ovarian tumors can develop from germ cells, responsible 
for producing ova, and sex-cord stromal cells, which generate reproductive 
hormones.  Consequently, the variety of histological subtypes of ovarian cancer 
contributes to the heterogeneity of this disease (9).  Furthermore, specific 
subtypes are associated with different degrees of aggressiveness, especially with 
regards to clinical characteristics, survival, and genetic alterations.  Interestingly, 
a retrospective study by Hollingsworth et al. provided strong evidence of an 
association between the degree of tumor vascularization and overall survival 
(10).   
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Figure 1.  Ovarian surface epithelium.  The origin of ovarian cancer has been traditionally 
attributed to the OSE (arrow).  OSE tends to have a simple cuboidal or low columnar morphology 
and is separated from the ovarian cortex by a distinct basement membrane.  Hematoxylin and 
Eosin stain, Original Magnification, 166x with correction factor.  
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Pathogenesis 
 
The etiology of ovarian cancer remains unclear, nevertheless, several 
hypotheses have been proposed for the pathogenesis of ovarian cancer.  First, 
“incessant ovulation” postulated by Fathalla in 1971 suggests that repetitive OSE 
trauma and repair, in addition to exposure to an estrogen-rich follicular fluid, 
promotes the mitotic activity of OSE which increases the likelihood of genetic 
alterations that eventually lead to malignant transformation (11).  Moreover, in 
vitro experiments by Nicosia et al. and Godwin et al. confirmed increased mitotic 
activity of rabbit OSE with chromosomal aberrations, proliferation or formation of 
preneoplastic lesions as a consequence of repetitive ovulation (12, 13).  This 
hypothesis is further supported by the decreased risk for disease associated with 
multi-parity and use of oral contraceptives, emphasizing a correlation between 
the number of ovulatory cycles with ovarian cancer risk (14).   
Second, the gonadotropin stimulation hypothesis, proposed by Stadel in 
1975 and expanded by Cramer and Welch suggests that excessive exposure to 
the gonadotropins, particularly follicle stimulating hormone (FSH) and luteinizing 
hormone (LH), can directly and indirectly stimulate OSE to form inclusion cysts 
derived from crypts or invaginations in the epithelium (15, 16).  FSH targets 
granulosa cells of the ovarian follicle, whereas LH targets theca, granulosa, and 
luteal cells (17).  These hormones bind specific receptors on the surface of target 
cells and activate intracellular second messenger signaling (17).  Likewise, in 
vitro studies demonstrate increased proliferation of OSE in response to both FSH 
and LH (18).  Similar to the incessant ovulation hypothesis, this theory is further 
supported by the decreased risk for ovarian cancer associated with multi-parity 
6 
and use of oral contraceptives.  In addition, this model also predicts increased 
risk associated with age, since levels of both gonadotropins, FSH and LH, are 
elevated in postmenopausal women (18).   
Last, the Müllerian system hypothesis, which as an alternative to a 
coelomic cell of origin, attributes the source of ovarian cancers to tissues that are 
primary or secondary derivatives of the Müllerian system, such as the fimbriated 
end of the fallopian tube (7, 19, 20).  Histological similarities among epithelia 
lining inclusion cysts, paraovarian cysts, and fallopian tube have been well 
documented, as have similarities among carcinomas arising from the ovary, 
fallopian tube, and peritoneum (19, 20).  This hypothesis, then, would explain 
why epithelial ovarian neoplasms present as morphological derivatives of 
epithelia of the fallopian tube (serous adenocarcinoma), uterus (endometriod), 
and endocervix (mucinous adenocarcinoma) without requiring an intermediate 
metaplastic step (19).  
 
Molecular Alterations 
In general, different cell types are regulated by specific genes.  Therefore, 
determining the impact of specific inherited or acquired genetic alterations may 
aid in the characterization of tumors and, thus, identification of their cell of origin.  
There are two classes of genes, oncogenes and tumor suppressor genes, which 
have been implicated in tumor pathogenesis.  Oncogenes encode proteins that 
stimulate growth, whereas tumor suppressor genes encode proteins that inhibit 
proliferation of normal cells (21).  In cancer, activation of proto-oncogenes occurs 
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in a single allele by mutation, over-expression, or translocation, so that 
oncogenes are referred to as dominant transforming genes.  Conversely, tumor 
suppressor genes are inactivated in cancer and are considered recessive 
transforming genes because loss of both alleles or loss of heterozygosity (LOH) 
is required for neoplastic transformation (21).   
Several tyrosine kinases have been identified as oncogenes, however 
overexpression and/or amplification of the epidermal growth factor (EGF) and 
human epidermal growth factor 2 derived from neuroblastoma (Her2/neu) 
receptors are most frequently observed in ovarian tumors and are associated 
with a very poor prognosis (22).  These receptors target phosphatidylinositol-3-
kinase (PI3K), an intracellular kinase, and result in aberrant autocrine/paracrine 
signaling (23).    
Several lines of evidence suggest that, re-expression of homeobox (HOX) 
genes, which regulate differentiation of Müllerian derived cells during 
development, may also contribute to the differentiation of ovarian carcinomas 
(23).  Furthermore, in vitro studies indicate differential expression of HOX 9, 10, 
and 11 in transformed mouse OSE results in serous, endometrioid and mucinous 
tumors, respectively (24).   
The most frequent genetic aberration of a tumor suppressor gene occurs 
in the p53 gene.  Normally, p53 acts as a transcriptional regulator and is often 
referred to as the guardian of the genome.  Investigators have identified several 
p53 mutations, most of which occur in highly conserved regions of the gene and 
are of functional importance (25).  Specifically in ovarian cancer, the presence of 
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putative precursor alterations in p53 staining or „p53 signatures‟, accumulate in 
tubal epithelium of women at risk of developing ovarian carcinomas (women with 
BRCA mutations) and pre-invasive lesions (26).  Moreover, the p53 signature 
characterizes high-grade serous histological subtypes (26).   Although a 
preclinical stage has not been observed, identifying recurrent genetic mutations 
or „signatures‟ warrants further investigation.   Independent of its cell of origin the 
pathogenesis of EOC remains complicated and not well understood. 
 
Detection 
Eradication of this “silent” disease depends, in part, on an effective early 
detection method.  A major prognostic factor is tumor stage at diagnosis and 
since most stage I ovarian cancers can be cured with conventional treatment, 
detection at a preclinical or early stage would have an impact on overall survival. 
An effective screening strategy requires a high sensitivity (true positive rate or 
probability that a subject with cancer will have a positive result), >75%, but even 
higher specificity (1-false positive rate or probability that a subject without cancer 
will show a negative result), >99.6%, in order to achieve a positive predictive 
value of 10% and avoid unnecessary surgery (27).  Current screening strategies 
have centered on transvaginal ultrasonography (TVS) and tumor markers or a 
combination of these two approaches.  Unfortunately, these methods alone or in 
combination do not satisfy the aforementioned criteria.   
Although, TVS can provide precise imaging of the ovaries, in practice it is 
incapable of distinguishing small cancerous lesions from benign masses (28).  In 
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addition, three major trials conducted in the US, UK, and Japan revealed 
limitations in both sensitivity and specificity (29-31) and have raised concerns 
about cost-effectiveness.   
Research of potential biomarkers has largely focused on the serum tumor 
marker cancer antigen 125 (CA125), a large surface glycoprotein thought to play 
a role in epithelial cell attachment.  At present, CA125 is the gold standard for 
ovarian cancer detection; however, it has limitations in sensitivity because only 
about 50% of women with stage I have an elevated CA125 level.  Furthermore, 
CA125 lacks specificity, especially in premenopausal women, where many other 
conditions of the genital tract can produce an elevated CA125 level, for instance 
endometriosis.  Specificity has been improved when CA125 is monitored over 
time or paired with TVS (27, 32) but still does meet the stringent criteria for an 
effective screening strategy.  
Several emerging biomarkers currently under investigation for early 
detection of ovarian cancer appear promising.  Of particular interest due to its 
role in regulation of the proangiogenic cytokine, vascular endothelial growth 
factor (VEGF), is the naturally occurring phospholipid, lysophosphatidic acid 
(LPA).  Independent reports by Xu et al. and Sutphen et al. have found elevated 
LPA serum levels in 90% of stage I patients and elevated LPA levels in 
preoperative samples compared to healthy controls, respectively (33, 34).  
Furthermore, recent reports from Anderson et al. and Badgwell et al. 
demonstrate significantly elevated urinary levels of B-cell lymphoma-2 (Bcl-2) 
and mesothelin, respectively, in addition to complementarity with CA125 (35, 36).  
10 
Further validation of these emerging biomarkers in combination with other 
markers is required and could provide a convenient, non-invasive and cost-
effective strategy for early detection of ovarian cancer.       
 
Angiogenesis 
 
 Angiogenesis is the formation of new blood vessels from pre-existing 
vasculature (37).  This process is strictly regulated by angioregulators, which are 
defined as endogenous factors that are angiogenic and promote angiogenesis, or 
angiostatic and inhibit angiogenesis.   
Embryonic development, growth and maintenance of cells and tissues are 
dependent on a vascular supply (38).  Although most vasculature in the adult is 
quiescent, physiological angiogenesis occurs during wound healing and 
prominently in the female reproductive system, pertinent to this work most 
notably taking place in the ovary (39).  Dysfunctional or uncontrolled 
angiogenesis leads to several pathological conditions such as chronic 
inflammation (40), immunological diseases (41), and cancer (42).  Elucidating 
which factors positively or negatively regulate this process has been a great 
challenge.  However, ongoing research continues to unravel the intricate 
mechanisms involved in the tight regulation of pro- and anti-angiogenic signals. 
Angiogenesis can be triggered by several factors including metabolic 
stress, especially under hypoxic conditions, as well as, mechanical forces like 
shear stress induced by blood flow, and genetic mutations such as, activation of 
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oncogenes, like K-ras.  Regardless of the cause, angiogenesis involves a multi-
step and orderly process and initiated by the expression of angiogenic growth 
factors by tissues (37, 43).  The release of pro-angiogenic factors activates 
receptors of the endothelium so that and endothelial cells (ECs) begin to degrade 
their basement membrane (44, 45).  Once the ECs penetrate the basement 
membrane they migrate towards the angiogenic stimulus (46) and endothelial 
sprouting is initiated.  Sprout extension continues until individual sprouts join or 
anastomose and align with other sprouts or capillaries which results in tube 
formation (47).  This process continues until the angiogenic factors are down-
regulated or are counterbalanced by angiostatic factors.   
Although, regulation of angiogenesis is reliant on a delicate balance of 
angioregulators, most research, to date, has focused on positive regulators.  
VEGF has emerged as the most prominent angiogenic regulator and the VEGF 
pathway appears highly conserved among different species (48, 49).  Other pro-
angiogenic factors include basic fibroblast growth factor (bFGF), platelet derived 
growth factor (PDGF), angiopoietins, and the transcription factor hypoxia-
inducible factor-1 (HIF-1).  Conversely, studies aimed at identifying novel 
angiostatic molecules and elucidating the role of these endogenous inhibitors of 
angiogenesis are ongoing.  However, in general angiostatic regulators associate 
with the extracellular matrix and suppress angiogenesis by exerting inhibitory 
effects on EC migration or by stimulating apoptosis (50). 
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Ovarian Angiogenesis 
 During the ovarian cycle angiogenesis occurs around the growing follicle 
and developing corpus luteum which is self-limited or transient, and ceases once 
the cycle is complete (37).  In addition, studies have demonstrated hormonal 
shifts contribute to alterations of the ovarian vasculature (51).  Consequently, 
several reproductive disorders are associated with dysregulated angiogenesis 
and vascular regression, for example, endometriosis, polycystic ovary syndrome, 
and cancer.  Similar to embryonic angiogenesis, in the ovary angiogenesis is 
driven by growth factors and cytokines and mitigated by inhibitors of 
angiogenesis (52).  Therefore, the ovary provides a physiological model to study 
both pro- and anti-angiogenic mechanisms.      
 During follicular maturation, primary and early secondary follicles are 
surrounded by a single layer of capillaries.  Once changes in the oocyte occur 
and follicular cells proliferate and become more cuboidal, blood vessels begin to 
appear in late secondary follicles.  Ferrara et al. have established a critical role 
for the pro-angiogenic factor, VEGF, and in situ hybridization reveals high levels 
of VEGF expression are maintained as follicles develop (53, 54).  As a 
consequence, human follicular fluid is angiogenic (55).  Furthermore, in vivo 
studies neutralizing VEGF directly or via receptor inhibition showed marked 
inhibition of follicular development and a decrease in both endothelial cell 
proliferation and vascular area (55-57).        
The basement membrane keeps the blood vessels restricted to the theca 
layer and prevents invasion of the avascular granulose layer (58).  Just prior to 
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ovulation there is a surge in LH, which results in vasodilation of capillaries in 
addition to an increase in vascular permeability, tissue edema, and ischemia 
(59).  At ovulation, the breakdown of the basement membrane occurs in 
association with intense angiogenesis, concurrently the blood vessels invade the 
resulting corpus luteum.  More than 75% of cells are of vascular origin in the 
mature corpus luteum (60) and it receives one of the highest blood supplies per 
gram of tissue than any other organ (61).  Interestingly, the corpus luteum 
demonstrates angiogenic activity when transplanted into the hamster cheek 
pouch and rabbit cornea (39, 62, 63) 
 
Tumor Angiogenesis 
Folkman first hypothesized that tumor growth is dependent on 
angiogenesis (64).  Indeed, tumors cannot grow more than 1-2 mm in size unless 
they recruit their own blood supply.  Like normal physiological angiogenesis, to 
satisfy this requirement, neoplastic cells produce angiogenic factors, namely 
VEGF, which stimulate formation of new blood vessels from the endothelium of 
the pre-existing vasculature.  However, in contrast to the angiogenesis that takes 
place in the ovary, once tumor angiogenesis is initiated it continues indefinitely 
and only ceases when the tumor is completely ablated or the host dies (37).  
Folkman and colleagues aptly designated this time point the “angiogenic switch” 
which indicates an imbalance of angioregulators in favor of angiogenic factors 
and, thus, initiation of tumor angiogenesis.  Using in vivo model system Gullino et 
al. have demonstrated that angiogenic activity occurs prior to neoplastic 
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transformation (65), even in the absence of morphological changes (66, 67).  
Therefore, the angiogenic switch, serves as a control point for most solid tumors, 
including highly vascularized ovarian neoplasms.  
 Although, tumor angiogenesis parallels normal physiological 
angiogenesis, distinct differences in the intrinsic vasculature morphology and 
functionality are evident.  For instance, certain tumors demonstrate structural 
alterations in their capillary networks such as fenestrations in ECs and blind 
ends, in addition to occasional interruptions in the basement membrane (68, 69) 
and extensive tortuosity reflective of vascular compression.  Furthermore, the so-
called leaky vessels of tumor vasculature appear due to constant exposure to 
VEGF which increases in vascular permeability.  Distorted tumor vasculature is a 
direct result of dysregulated angiogenesis and is compounded by a continual 
outgrowth of the blood supply.  Alternative to traditional angiogenesis, 
vasculogenic mimicry suggests that in addition to ECs, pluripotent embryonic-like 
and highly aggressive tumor cells contribute to neovascularization in tumors (70).      
 Ovarian cancers have a propensity to be highly vascularized and often 
metastasize to the peritoneal lining.  Additionally once these tiny implants 
become vascularized, ascites accumulates in the abdomen, a clinical observation 
of progression (71).  Nicosia and colleagues have reported elevated levels of the 
angiogenic regulators, VEGF and HGF, in patients with benign ovarian cysts or 
functional cysts and patients with malignant tumors (72).  Moreover, in contrast to 
ascites, ovarian cyst fluid contains VEGF and demonstrates angiogenic 
properties (72).  Counter-intuitively, angiostatin (AS) (see below) and other anti-
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angiogenic plasminogen cleavage products are also present in malignant ascites 
fluid and contribute to its net angiostatic properties (73).   Therefore, since 
ovarian cancers are associated with the production of ascites and cyst fluids 
which contain positive and/or negative angioregulators, evaluation of 
angioregulators in bodily fluids may be clinically relevant for ovarian cancer.     
 
Angiostatin   
O‟Reilly et al. in Folkman‟s laboratory observed rapid angiogenesis and 
growth of residual tumors following surgical removal of primary tumors.  
Therefore, they postulated that although a primary tumor can stimulate 
angiogenesis locally, it is capable of inhibiting a secondary tumor at a distant site 
(74).  Inhibition of the distant metastasis was hypothesized to be a consequence 
of an unbalanced production of both positive and negative angioregulators by the 
primary tumor, where angiogenic regulators could promote angiogenesis of the 
primary tumor and angiostatic regulators could suppress metastatic growth.  In 
an effort to elucidate the phenomenon of inhibition of tumor growth by tumor 
mass, O‟Reilly discovered the first naturally occurring angiostatic regulator, AS.  
Interestingly, AS was purified from the serum and urine of mice bearing a Lewis 
lung carcinoma and supports the concept of tumor dormancy, whereby, AS 
generated by the primary lung tumor diffused into circulation and inhibited a 
distant metastatic growth (74).   
AS, is a 38 kDa internal cleavage product of the circulating zymogen, 
plasminogen (Figure 2) (74).  Paradoxically, AS is generated via proteolytic 
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cleavage by proteinases which are activated in response to an angiogenic 
signaling cascade.  Production of AS, then, illustrates the obligatory coupling of 
angiogenic and angiostatic regulators as a consequence of normal physiological 
angiogenesis.  AS was originally described to contain the first four kringle 
domains of plasminogen.  However, several studies have confirmed that a variety 
of proteases are able to cleave plasminogen creating different isoforms of AS 
with markedly different anti-angiogenic activity based on the presence of specific 
kringle domains (75).  For instance, kringle 5 appears to possess more potent 
angiostatic activity than other kringle domains, so that AS isoforms containing 
kringle 5 are more effective inhibitors (76, 77).  Functionally, AS inhibits migration 
and proliferation of ECs, most likely through its cell surface receptor ATP 
synthase (78).  Consequently, delineating the molecular mechanisms involved in 
production, regulation, and dysregulation of AS may be clinically useful for 
therapeutic intervention.  
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Figure 2.  Schematic of angiostatin structure and generation by proteolytic cleavage of 
plasmin and plasminogen.  The asterisks indicate where plasminogen activators (urokinase and 
tissue plasminogen activator) cleave the zymogen to yield plasmin, an active fibrinolytic serine 
proteinase.  Plasmin undergoes autoproteolysis in the presence of a free sulfhydryl donor to yield 
angiostatin as described by O‟Reilly et al. (74).    
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Axon Guidance and Angiogenesis 
 The fundamental principles of blood vessel and nerve fiber growth involve 
sprouting, migration, and proliferation of ECs and axons, respectively in response 
to concentration gradients.  These networks develop in response to common 
attractive and repulsive guidance cues, such as semaphorins which bind to 
cellular receptors to facilitate regulation.  Consequently, specialized ECs and 
axons, identified as tip cells and growth cones, respectively, undergo cytoskeletal 
rearrangement and extend filopodia to become motile and invasive (79, 80).  
Intriguingly, many genes thought to be specific to neurons also play a role in 
angiogenesis, suggesting a developmental similarity between nervous tissue and 
vasculature.  This is further supported by the observation that blood vessels and 
nerve fibers often align in parallel in order to provide oxygen and nutrients to the 
peripheral nervous system and arterial innervation (79, 81).  Therefore, further 
investigation of these multifaceted cues may identify a novel angiostatic 
regulatory mechanism. 
 
Semaphorins 
 
 Semaphorins are a large family of cell associated proteins.  Although, 
initially identified to be involved in axon guidance and growth cone collapse, 
semaphorins have been found to be widely expressed outside the nervous 
system.  There are eight classes of semaphorin genes and more than 30 
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members, which are implicated in several biological functions including cell 
adhesion, migration, and angiogenesis (82).   
Semaphorins are divided based on structure: classes 1 and 2 consist of 
invertebrate semaphorins, whereas classes 3 to 7 comprise vertebrate 
semaphorins and class V consists of semaphorins encoded by viral genomes.  
All semaphorins are characterized by a conserved 500 amino acid, cysteine-rich, 
extracellular „sema‟ domain, which mediates binding specificity and is necessary 
for signaling (82).  The sema domain has a seven-blade β-propeller motif and 
structural similarity to α-integrins (83).  Additionally, semaphorins contain a 
putative cysteine-rich protein binding domain known as a plexin-semaphorin-
integrin (PSI) domain located adjacent to the sema domain (84).  Class 3 
semaphorins are unique in that they are the only secreted family members and 
are further distinguished by the presence of a basic C-terminal domain which is 
required for receptor binding (Figure 3).  Class 4-7 semaphorins are anchored to 
the membrane and distinguished by structural features that include 
immunoglobulin-like domains, thrombospondin repeats (class 5), or a 
glycophosphatidylinositol (GPI) anchor (class 7).    
 
Receptors 
 There are two classes of high-affinity receptors for semaphorins, plexins 
and neuropilins (NPs) (85-87).  In humans, plexins are divided into four 
subfamilies (A,B, C, D) and expression is ubiquitous, whereas invertebrates only 
have two plexin genes which are more exclusively expressed in the nervous 
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tissue (86).  Like semaphorins, plexins contain a „sema‟ domain in the 
extracellular moiety in addition to 3-4 PSI domains (Figure 3).  Although, the 
putative cytoplasmic domain of plexins lacks endogenous tyrosine kinase activity, 
this segment has demonstrated a weak intrinsic GTPase-activating protein (GAP) 
which facilitates R-ras inactivation (88).  Most class 4-7 semaphorins directly bind 
to plexins and activate plexin-mediated signal transduction.  In contrast to other 
types of semaphorins, class 3 semaphorins (SEMA3s) are unable to directly bind 
plexins and, therefore, utilize the NPs, NP-1 and NP-2, as co-receptors, with the 
exception of SEMA3E.   
NPs are only expressed in vertebrates and are single-span 
transmembrane glycoproteins characterized by two extracellular complement-like 
(CUB) domains (designated a1/a2 domains) as well as, two FV/FVIII coagulation 
factor-like domain (designated b1/b2 domains) and a meprin-like MAM domain 
(designated as c domain) (Figure 3) (85, 86, 89).  NPs have a relatively short 
cytoplasmic domain and no signaling consensus sequence has been identified.  
Interestingly, although the NPs do not interact with membrane-bound 
semaphorins, they serve as co-receptors for VEGF family members where signal 
transduction is facilitated via activation of tyrosine kinase receptors, vascular 
endothelial growth factor receptor 2 (VEGFR2) and vascular endothelial growth 
factor receptor 3 (VEGFR3) (89-92).  Additionally, NPs also interact with other 
heparin-dependent ligands such as, bFGF, placenta growth factor-2 (PlGF-2) 
and hepatocyte growth factor (HGF) (93).  However, the interaction between 
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VEGF family members and NPs suggests a potential role in vascular and tumor 
biology for NPs in addition to their SEMA3 ligands.  
In contrast to most biological signaling pathways which are unidirectional, 
semaphorin signaling is bidirectional, occurring in an autocrine or paracrine 
manner.   These guidance cues operate in a mode similar to that of a traffic sign, 
harboring the ability to provide two alternative signals, specifically inhibition or 
induction of cell motility.  The underlying mechanisms driving semaphorin 
signaling are unclear, studies suggest that this dynamic signaling is dependent 
upon the oligomerization of specific receptors and distinct downstream molecular 
pathways (94).  Although counter-intuitive, this bi-directional semaphorin 
signaling is similar to the action of angiogenic and angiostatic regulators 
governing angiogenesis.  Consequently, bidirectional semaphorin signaling 
and/or its dysregulation have implications for cell motility and invasion, and 
especially as that pertain to tumor angiogenesis and may promote tumor 
progression.  
 
Class 3 semaphorins 
In recent years, the putative role of SEMA3 signaling has expanded 
beyond the nervous system.  SEMA3s are approximately 100 kDa and consist of 
seven soluble proteins designated SEMA3A-G (95).  As secreted proteins, 
SEMA3s specifically target cells expressing NPs, most notably neurons, ECs, 
epithelial cells (like OSE) and tumor cells.  As a result, SEMA3s involved in axon 
guidance and angiogenic VEGF family members share NP receptors.  There is a 
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high degree of specificity in binding between the NPs and their ligands.  NP-1 
has a higher affinity for SEMA3A, in addition to VEGF165, PlGF-2, HGF, whereas 
NP-2 has a higher affinity for SEMA3F, SEMA3G, and VEGF145.  However, 
SEMA3B, SEMA3C, VEGF165, and VEGF121 can bind either NP receptor (85, 86, 
89, 91, 93, 96-101).  SEMA3E is the only SEMA3 that does not bind NP 
receptors, however, it does directly bind to Plexin D1 (102).  
Consequently, inter-relationships between axon guidance SEMA3s and 
angiogenic VEGF with NP, VEGFR, and plexin receptors potentially regulate a 
wide range of signaling pathways involved in cell adhesion, migration, tube 
formation, sprouting, permeability, angiogenesis, and metastasis.  For instance, 
SEMA3A initially identified to repel axon movement also inhibits EC and tumor 
cell motility (103, 104).  Clearly, investigating the mechanisms governing the 
molecular cross-talk between the variety of cellular mechanisms influenced by 
SEMA3 signaling has potential prognostic and therapeutic implications. 
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Figure 3.  Schematic representation of class 3 semaphorins and receptors, neuropilins and 
plexins, structure.  SEMA3s function in a paracrine manner which is mediated through specific 
binding of SEMA3s to NP receptors on the surface of target cells followed by complexing with 
another transmembrane receptor family, known as Plexins, and subsequent activation of 
intracellular signaling pathways.   
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Semaphorin 3F 
Semaphorins have been studied extensively in vertebrates, and was 
initially identified to play an important role in brain development as a potent 
chemo repellant to axonal extensions and neuronal migration (105).  Current 
research has established additional biological functions for SEMA3F outside the 
nervous system, most notably in regard to angiogenesis, as well as tumor 
progression and metastasis.  In fact, the SEMA3F gene was originally isolated 
from 3p21.3, a region known to be deleted in lung, breast, and ovarian cancers 
(106, 107) (remove 106 and replace with 1996 Roche Oncogene #158).  
Exogenous SEMA3F expression in tumor cells resulted in reduced tumor 
formation in nude mice thereby implicating SEMA3F as a tumor suppressor 
(108).           
Since SEMA3F and VEGF share a common receptor, several studies 
have investigated the antagonistic relationship between SEMA3F and VEGF 
which is attributed, in part, to overlapping ligand-binding regions in the b1/b2 
extracellular domains of both NPs (Figure 3).  In a lung cancer cell line, Roche et 
al. have suggested, in addition to competition for binding, that an alternative 
mechanism driving the angiostatic activity of SEMA3F is down regulation of 
VEGF mRNA via inhibition of HIF-1α expression (109).  Likewise, 
immunohistological studies indicate a loss of SEMA3F expression with advanced 
stage of disease and while VEGF expression is increased (110).  Furthermore, in 
ovarian cancer the ratio of VEGF to SEMA3 may have potential prognostic 
implications, such that patients with a higher VEGF/SEMA3 ratio are associated 
with poorer survival compared to patients with a lower VEGF/SEMA3 ratio (111).   
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 Although several signaling pathways are affected by SEMA3F, including 
inactivation of the mitogen-activated protein kinase (MAPK) and Akt pathways,  
regulation of SEMA3F remains unclear (109).  Interestingly, there is some 
evidence suggesting that p53 and/or the transcription factor zinc finger E-box 
binding homeobox 1 (ZEB-1) may be involved (112, 113).  In summary, 
considering the inter-relationships and parallels during axon guidance and 
angiogenesis, further studies are warranted to elucidate the molecular 
mechanisms regulating SEMA3F function and dysregulation, especially as they 
impact ovarian tumor formation and progression.    
 
Central Hypothesis 
 
Dysregulation of angiostatic regulators plays a role in ovarian cancer. 
 
Specific Aims 
 
 Ovarian cancers develop into morphologically complex, highly 
vascularized structures.  Although, the role of angiogenic regulators has been 
well documented the role of angiostatic regulators has been understudied.  
Therefore, this study examined two angiostatic regulators, angiostatin and 
semaphorin3F, in ovarian cancer.  Three specific aims were proposed to address 
this hypothesis: 
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1) Evaluate the sensitivity and specificity of urinary angiostatin as a 
potential biomarker for ovarian cancer. 
2) Establish the clinical relationship between semaphorin3F expression 
and ovarian cancer progression.    
3) Expand upon the antagonistic relationship between VEGF and 
semaphorin3F, by examining semaphorin3F regulation and 
semaphorin3F-mediated telomerase activity in ovarian cancer cells. 
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CHAPTER II 
 
URINARY ANGIOSTATIN LEVELS ARE ELEVATED IN PATIENTS WITH 
EPITHELIAL OVARIAN CANCER 
 
Abstract 
 
The poor prognosis associated with EOC is due to the lack of overt early 
symptoms and the absence of reliable diagnostic screening methods.  Since 
many tumors over express angiogenic regulators, the purpose of this study was 
to determine whether elevated levels of the angiogenic or angiostatic molecules 
VEGF, HGF, endostatin (ES), and AS were elevated in plasma and urine from 
patients with EOC. 
VEGF, HGF, ES and AS were assayed by ELISA in samples from pilot 
cohort consisting of healthy women (N=48; pre-menopausal N=23, post-
menopausal N=25), women with benign gynecological disease (N=54), patients 
with primary peritoneal cancer (PP) (N=2) and EOC (N=35).  Wherever possible, 
parallel serum samples were measured for CA125 levels by ELISA. 
AS was the angioregulator that independently discriminated EOC patients 
from healthy individuals.  Levels of urinary AS (uAS) from healthy individuals or 
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women with benign gynecological disease averaged 21.4 ng/mL±3.7 and 41.5 
ng/mL±8.8, respectively.  In contrast, uAS averaged 115 ng/mL±39.2 and 276 
ng/mL±45.8 from women with Stage I (N=6) and late stage (N=31) EOC, 
respectively.  Further, uAS was elevated in EOC patients regardless of tumor 
grade, stage, size, histological subtype, creatinine levels, menopausal status, or 
patient age, but appeared to complement CA125 measurements. 
Levels of AS are elevated in the urine of patients with EOC and may be of 
diagnostic and/or prognostic clinical importance.  Further studies of uAS as a 
biomarker for EOC alone or in combination with other markers are warranted. 
 
Introduction 
 
 EOC is the most lethal gynecologic neoplasm.  In 2009, it will strike over 
21,000 women, seventy percent of whom will be first diagnosed at advanced 
stage (114).  As a result, less than 50 percent of patients are alive five years after 
initial diagnosis.  
 In order to detect early stages of EOC and avoid unnecessary surgery 
screening strategies require a sensitivity >75% and a specificity of 99.6% (27, 
115). Currently, three screening procedures are in use for EOC detection: 
bimanual pelvic examination, serum CA125 and transvaginal ultrasonography 
(TVS) (27, 115).  Pelvic examination is an important part of routine gynecologic 
examination but lacks sensitivity and specificity.  Although CA125 is elevated in 
80 percent of patients with EOC, its use as an early predictor of malignancy is 
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limited because only half the patients with stage I disease have elevated CA125 
levels.  In addition, CA125 lacks specificity as a screening procedure being 
elevated in a significant number of healthy women or in patients with benign 
ovarian lesions.  The pairing of TVS with CA125 improves specificity, although 
the former procedure is not practical for cancer screening because of its potential 
for false positive results and unnecessary surgery.  Unfortunately, these 
strategies alone or in combination do not satisfy the aforementioned criteria.  
Pairing of multiple markers and clinical symptoms is also being explored with 
promising, but yet unresolved clear advantages over CA125 toward early 
diagnosis (61, 116, 117).  Molecular alterations that occur in the early or 
recurrent cancer may serve as biomarkers of tumor growth and progression and 
may provide new approaches to detect EOC.  
 During the early tumor development, cells acquire the capacity to 
stimulate angiogenesis (53).  For instance, a primitive blood capillary with its 
surrounding fibrocollagenous stroma is found at the base of incipient papillae of 
ovarian serous neoplasms (118).  Experimental tumors cannot grow more than 2 
to 3 mm in size unless they are vascularized.  To satisfy this requirement, 
neoplastic cells produce angiogenic factors which stimulate formation of new 
vessels from the endothelium of the preexisting host vasculature (119).  The 
switch to an angiogenic phenotype during the early stages of tumor progression is 
modulated by both angiogenic and angiostatic molecules in a “Ying and Yang” 
fashion (119). Thus, evaluation of angioregulators‟ levels in body fluids may 
contribute to the early detection of EOC.  The angiogenesis-dependent nature of 
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tumor growth is particularly relevant for this cancer which can reach large 
proportions and correlations between microvascular density and tumor 
aggressiveness have been established (120).  Thus, analysis of angiogenic factors 
that regulate EOC growth and progression may have important implications for the 
diagnostic and prognostic evaluation of this disease.  
 Our lab previously reported that the cyst fluid of EOC contains large 
amounts of VEGF (72).  VEGF and basic fibroblast growth factor (bFGF) levels 
were evaluated in patients with benign ovarian cysts, functional cysts, borderline 
tumors, and patients with malignant tumors.  There was a marked difference in 
VEGF levels between malignant cysts and benign, borderline or functional cysts.  
Malignant neoplasms had an average 26-fold increase in VEGF over benign 
lesions and a 6-fold increase over borderline tumors.  Unlike VEGF, bFGF was 
generally very low or undetectable in malignant cysts and did not correlate with 
malignancy. We also found that VEGF levels in ovarian cyst fluid were 3-fold higher 
in 6 patients with evidence of disease 1-2 years after surgery (~50 ng/mL) as 
compared to 7 patients with no evidence of disease (~18 ng/mL) (72).  
Consequently, evaluation of circulating or excreted angiogenic and/or angiostatic 
markers may be clinically relevant for EOC.   
 Other studies have also shown that high intratumoral concentrations of 
VEGF and other angiogenic cytokines, such as HGF, may be reflected by elevated 
levels in peripheral blood, in urine and in effusions of patients with a wide spectrum 
of cancers, including EOC (121-124).  Malignant tumors also generate small 
inhibitors of angiogenesis such as ES, AS, and thrombospondin (73, 125-128).  
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Additionally, ES and AS have been reported at detectable levels in urine of patients 
with malignant disease and could, therefore, provide biomarkers for cancer (129-
131).  Given these reports along with our earlier finding of elevated VEGF in the 
cyst fluid of EOC (72), we sought to determine if plasma and urinary levels of the 
angioregulators VEGF, HGF, ES, and AS correlate with EOC disease status. 
 
Methods and Materials 
 
Patient cohort 
With prior institutional approval, urine and blood samples were collected 
from a cohort of healthy pre-menopausal (N=23) and post-menopausal (N=25) 
individuals, women with benign gynecologic disorders (N=54) and patients with 
EOC (N=35) or primary peritoneal (PP) cancer (N=2) at the H. Lee Moffitt Cancer 
Center and Tampa General Hospital in collaboration with the University of South 
Florida.  Two cases designated as low malignancy potential (LMP) tumors were 
also evaluated.  All except 8 specimens were collected prior to initial surgical 
cytoreduction while the latter 8 specimens presented with recurrent disease at 
the time of enrollment in this study.  In addition to EOC, the cancer category 
consisted of women diagnosed PP cancer, which is often related to EOC.  The 
samples collected from women with benign disease consisted of a broad range 
of ovarian and non-ovarian genital tract (GT) lesions (Table 1). 
Tissue blocks were identified and reviewed by SVN to confirm the 
histopathology of benign and malignant lesions, the latter according to FIGO 
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criteria.  The clinical databases of these women were also reviewed and 
information regarding patient age, tumor type, stage, grade, size, CA125 values 
and surgical and adjuvant treatment abstracted whenever available.  This 
information and tumor pathology were correlated with plasma and urinary levels 
of angioregulators, which are summarized in Tables 1 and 2, in a total of 141 
women. 
 
Sample preparation 
Urine and blood samples were collected from patients, anonymized and 
decoded to protect patient identity, and released from the tissue banks for this 
research project.  All samples were kept on ice following collection.  Urine 
samples were treated with a standard protease inhibitor cocktail (80 μg/ml 4-(2 
aminoethyl)-benzene sulfonyl fluoride, 200 μg/ml EDTA, 0.2 μg/ml leupeptin, 0.2 
μg/ml pepstatin, Sigma Scientific, St. Louis, MI) within minutes to a few hours of 
collection and centrifuged at 3000×g.  Urinary supernates and plasma samples 
were then aliquoted and stored at −20 °C for up to 4 years without change in 
activity. 
 
Enzyme-linked immunosorbant assay 
Angiogenic molecules were assayed using quantitative sandwich enzyme-
linked immunosorbant assay (ELISA) kits for VEGF, HGF, and ES (all kits from R 
& D Systems, Minneapolis, MN) according to the manufacturer‟s instructions.  
uAS was assayed using lysine-ELISA as described previously by Cao et al (129).  
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In accordance with previous studies (129), uAS threshold levels were set to 
include 95% of AS values of urine samples from healthy women.   
When not derived from clinical data, CA125 levels in subjects‟ plasma 
were assayed by individual ELISA tests (Bio-Quant, San Diego, CA) according to 
the manufacturer‟s instructions.  The enzymatic reactions were detected at 450 
nm or 492 nm using a Dynex MRX plate reader (Dynex Technologies, Chantilly, 
VA) and results were expressed as the mean absorbance of triplicate samples ± 
S.E. for VEGF, HGF, ES, while CA125 and AS results were expressed as the 
mean of duplicate samples. 
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Table 1.  Histological diagnoses and clinical characteristics of the study 
cohort. 
 
 
Sample 
Cancer 
Pathological 
Parameters 
Age 
mean ± SE 
AS 
mean ng/ml ± SE 
Healthy (48)  53.5 ± 1.7 21.4 ± 3.7 
  Pre-Menopausal (23)  44 ± 1.6 21.4 ± 5.8 
  Post-Menopausal (25)  62 ± 1.2 21.4 ± 4.9 
Benign (54)  54.9 ± 2.0 41.5 ± 8.8 
  Cysts (12)   43.7 ± 18.9 
  Papillomatosis (1)   180 
  Fibroma/Adenofibroma (8)   25.2 ± 9.6 
  Teratoma (3)   15.6 ± 0 
  Serous Cystadenoma (12)   74.4 ± 29.8 
  Muscinous Cystadenoma 
(2) 
  15.62 
  Genital Tract Lesions (16)   22.9 ± 5.1 
Cancer (37)  63.1 ± 2.2 247 ± 37.6 
  Mucinous (7)   274 ± 129.3 
  Endometriod (1)   15.62 
  Serous (27)   251 ± 39.9 
 LMP (2)  126 
 Grade 1 (9)  272 ± 105 
 Grade 2 (10)  189 ± 42.3 
 Grade 3 (18)  269 ± 53.2 
 Stage I (6)  115 ± 39.2 
 Stage II (1)  208 
 Stage III (20)  246 ± 49.2 
  Primary Peritoneal (2)  59 216 
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Western blot analysis 
 For Western blot analysis, plasma samples were solubilized in SDS gel 
loading buffer (60 mM Tris base, 2% SDS, 10% glycerol, and 5% β-
mercaptoethanol), separated via 10% SDS-PAGE and electroblotted onto PVDF 
membranes by wet transfer.  Immunoblotting was performed using antibodies 
directed against the kringle 1-3 regions of human plasminogen (1:1000, R & D 
Systems, Minneapolis, MN).  β-actin (1:10,000, Sigma-Aldrich, St. Louis, MO) 
was used as a loading control.  Blots were visualized using the ECL Western 
Blotting Analysis System (Amersham Pharmacia Biotech, Piscataway, NJ) 
according to the manufacturer‟s instructions.  Blots were analyzed and scanned 
with ImageQuant image analysis software (GE Healthcare Bio-Sciences Corp., 
Piscataway, NJ).  Values reported for AS were normalized to the blots‟ respective 
β-actin levels.  
       
Statistical analysis 
Samples for VEGF, HGF, and ES were run in triplicate, whereas samples 
for CA125 and AS were run in duplicate and the data subject to descriptive, one-
way Kruskal Wallis, Spearman correlation, and/or receiver operator curve and 
area under the curve (ROC-AUC) analyses.  P-values <0.05 were considered 
statistically significant. 
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Results 
 
uAS levels are elevated in EOC patients 
 We evaluated the levels of VEGF, HGF, and ES in the plasma and urine 
of healthy controls and of patients with benign gynecologic disorders or EOC; 
uAS was also evaluated.  Kruskal Wallis global test indicated seriousness of 
clinical status (EOC > benign lesions > healthy status) correlated with plasmatic 
(p ≤ 0.0016) and urinary (p ≤ 0.01) VEGF, plasmatic HGF (p ≤ 0.0021), plasmatic 
ES (p ≤ 0.01) and uAS (p < 0.0001) (Figures 4, 5A, Table 2).  uAS was the 
variable that independently discriminated EOC patients from healthy controls.  
Although there have been some studies reporting the detection of non-ovarian 
cancers by measuring various proteins in urine, only few reports have been 
recently published relative to EOC detection in this biological fluid (35, 123, 129) 
and to our knowledge this is the first report of AS as a biomarker of EOC.  
Since plasminogen interfered with the measurement of plasmatic AS by ELISA, 
plasmatic AS was detected in representative samples (6/group) by Western 
immunoblotting and did also appear to correlate with disease status (Figure 5B).  
We believe uAS is better because renal filtration allows smaller, positively 
charged fragments of plasminogen, like AS, but not its higher molecular weight 
precursor, to be excreted in urine.  In addition, creatinine levels measured at the 
time of urine collection indicated that elevated uAS in cancer patients was not 
related to renal dysfunction (data not shown). 
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Table 2. VEGF, HGF, ES, and AS in the Study Cohort as Descriptive Statistical Information
Angiogenic Factor # Mean SE Median Min, Max Chi-Square p-value 
  P U P U P U P U P U P U 
VEGF           (pg/mL) 
Normal 
Benign 
Cancer 
Global Test 
Normal v Benign 
Normal v Cancer 
Benign v Cancer  
 
24 
54 
39 
117 
78 
61 
91 
 
33.65 
52.72 
89.28 
 
 
47.5 
57 
86.52 
 
 
1.92 
5.37 
17.97 
 
 
4.51 
4.49 
12.3 
 
 
31.2 
31.2 
44 
 
 
42.5 
39.5 
60 
 
 
31.2, 77 
31.2, 225 
31.2, 550 
 
 
24, 112 
31.2, 152.73 
31.2, 395 
 
 
 
 
 
12.81 
6.31 
11.93 
3.12 
 
 
 
 
 
10.2 
0.43 
6.12 
4.35 
 
 
 
 
0.0016 
0.012 
0.0006 
0.0773 
 
 
 
 
0.01 
0.51 
0.01 
0.04 
HGF              (pg/mL) 
Normal 
Benign 
Cancer 
Global Test 
Normal v Benign 
Normal v Cancer 
Benign v Cancer 
 
24 
54 
39 
117 
78 
61 
91 
 
591.44 
650.39 
1566.3 
 
 
565 
496 
994 
 
 
42.29 
41.68 
528.7 
 
 
89.2 
38.8 
136.4 
 
 
565 
598.8 
900 
 
 
375 
385 
760 
 
 
220, 1177 
119.2, 1450 
260, 16000 
 
 
250, 1664.3 
25, 1160 
250, 4026.3 
 
 
 
 
 
12.37 
0.13 
12.51 
5.86 
 
 
 
 
 
12.9 
0.11 
6.76 
10.7 
 
 
 
 
0.0021 
0.7168 
0.0004 
0.0155 
 
 
 
 
0.0016 
0.7409 
0.0093 
0.0011 
 
ES                (ng/mL) 
Normal 
Benign 
Cancer 
Global Test 
Normal v Benign 
Normal v Cancer 
Benign v Cancer 
 
24 
54 
3 
117 
78 
61 
91 
 
19.99 
16.46 
25.51 
 
 
 
8.49 
8.44 
11.38 
 
 
 
0.51 
0.92 
2.81 
 
 
 
1 
0.67 
1.58 
 
 
19.87 
16.4 
22 
 
 
 
7.5 
7.4 
10 
 
 
 
15.01, 24.57 
7.03, 36.8 
7.8, 109 
 
 
 
 
3.9, 19 
3.6, 19 
3.9, 62.5  
 
 
 
 
 
12.81 
6.31 
11.93 
3.12 
 
 
 
 
 
10.2 
0.43 
6.12 
4.35 
 
 
 
 
0.0016 
0.012 
0.0006 
0.0773 
 
 
 
 
0.01 
0.51 
0.01 
0.04 
AS                (ng/mL) 
Normal 
Benign 
Cancer 
Global Test 
Normal v Benign 
Normal v Cancer 
Benign v Cancer 
 
24 
54 
39 
117 
78 
61 
91 
 
ND 
ND 
ND 
 
 
 
21.1 
41.5 
241 
 
 
 
ND 
ND 
ND 
 
 
 
5.5 
8.8 
36 
 
 
 
ND 
ND 
ND 
 
 
 
15.62 
15.62 
192 
 
 
 
ND 
ND 
ND 
 
 
 
15.62, 148 
15.62, 336 
15.62, 1000 
 
 
 
 
ND 
ND 
ND 
ND 
 
 
 
 
59.64 
2.83 
33..39 
42.14 
 
 
 
 
ND 
ND 
ND 
ND 
 
 
 
 
<0.0001 
0.0926 
<0.0001 
<0.0001 
P, plasma; U, urine; ND, not determined 
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Figure 4.  Plasma and urinary levels of angiogenic regulators are elevated with EOC 
progression.  ELISA was utilized to measure (A.) VEGF (mean pg/ml ± S.E.), (B.) HGF (mean 
pg/ml ± S.E.) and (C.) ES (mean ng/mL ± S.E.) in the plasma and urine of healthy volunteers 
(N=24) and of patients with benign gynecologic disorders (N= 54) or EOC (N= 39).  Samples 
were examined in triplicate and the data expressed as mean ± S.E/category (normal-purple, 
benign-pink, cancer-green). Lined bars–plasma; Solid bars-urine; * p≤0.01 
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Figure 5.  AS levels are elevated in EOC patients.  (A.) uAS was evaluated using lysine-ELISA.  
Samples were examined in duplicate and the data expressed as mean ng/mL ± S.E. per 
category.  Healthy individuals were further divided based on menopausal status (inset).  (B.) 
Plasmatic AS was detected in representative samples (6/category) by Western immunoblotting 
using a monoclonal antibody against the kringle 1-3 regions of human plasminogen.  
Densitometric analyses are expressed as relative intensity of plasmatic AS levels normalized to 
β-actin protein levels.  Normal-purple; Benign-pink; Cancer-green; Lined bars–plasma; Solid 
bars-urine; ** p≤0.0001 
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Clinical status 
Based on the initial findings of a better discriminating effectiveness of AS, 
we expanded our analysis with regards to clinical parameters in this cohort of 
healthy controls, women with benign gynecologic disorders and patients with 
EOC.  Though this cohort comprises a small pilot study, it is representative of our 
institutional clinical practice in regard to EOC histology, grade and stage 
distribution.   
The amount of uAS was generally negligible (average of 21.4 ng/mL±3.7; 
95% confidence interval = 13.9-28.9) in healthy controls regardless of 
menopausal status (Figure 5A inset) with only 8% of samples above a previously 
established cutoff threshold of 16 ng/mL for uAS in normal individuals (129, 131) 
(Figure 5A, Table 1).  In contrast, uAS associated with EOC and PP cancer was 
generally >10x than found in healthy controls with an overall mean value of 249 
ng/mL±39.7 and 216 ng/mL, respectively (95% confidence interval of all cancers 
= 171-323.5) (Figure 6A, Table 1).  Interestingly, 5/37 and 3/37 of EOC patients 
had uAS ≤16 and ≤50 ng/mL, respectively, but it is noteworthy that two samples 
were derived from patients with mucinous ovarian cancer and one was derived 
from endometrioid ovarian cancer (Figure 6A). 
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Figure 6.  uAS levels are elevated in EOC patients.  Urinary samples were analyzed in 
duplicate by lysine-ELISA and data expressed as mean ng/mL per patient in (A.) healthy controls 
and cancer histological types (muc, mucinous; serous, serous adenocarcinoma; PP, primary 
peritoneal) as well as serous tumor grade; (B.) according to tumor stage including recurrent EOC, 
grade and size and (C.) among women with benign ovarian and non-ovarian genital tract (GT) 
lesions; 2 cases of LMP were also included.  Mean uAS (ng/mL) indicated for each category.  
ROC-AUC analyses of uAS in EOC vs (D.) healthy controls and (E.) women with benign 
gynecologic diseases. 
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The distribution of uAS was evaluated by histological EOC subtype, 
including serous carcinomas representing over 75% of the pilot cohort.  There 
was a trend for elevated uAS with increasing tumor grade (189 ng/mL±42.3 for 
Grade 2 neoplasms to 269 ng/mL±53.2 for Grade 3 carcinomas) and especially 
stage (115 ng/mL±39.2 for Stage I to 208, 246 ng/mL±49.2, and 333 ng/mL±90.5 
for Stages 2, 3, and recurrent respectively) although these were not statistically 
different (Figures 5A, 6A-B).  Of interest, on average, uAS levels of Stage I EOCs 
were 5 and 3 fold higher than in healthy controls or women with benign disease, 
respectively; likewise, although not statistically different (p ≤ 0.1232), uAS Stage I 
was 2 fold lower than late stage EOC (Figures 5A, 6B).  Similarly, there was a 
non-statistical tendency for elevated uAS with tumor size (108.7 ng/mL±34.9, 
393.3 ng/mL±112.2, 247.6 ng/mL±42.3, for microscopic, <2 cm, and >2 cm, 
respectively) (Figure 6B).  In contrast, patient age did not appear to be related to 
elevated uAS (Table 1).   
uAS was also analyzed in women with benign ovarian lesions or non-
ovarian GT lesions (Figure 6C, Table 1).  uAS in patients with benign ovarian 
lesions displayed a mean level ≤ 50 ng/mL with nearly 82% of samples <16 
ng/mL and 7/54 samples with levels ranging from 64 to 176 ng/mL (95% 
confidence interval = 24.9-73.9) (Figure 6C).  Interestingly, the 3 highest uAS 
values were noted in 1 case of serous surface papillomatosis and 2 serous 
cystadenomas; unfortunately, these were blinded samples and follow-up 
information on these patients was not available.         
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ROC analyses indicated sensitivity and specificity of uAS for distinguishing 
healthy controls from cancer patients as 88% and 92.3%, respectively (Figure 
6D).  Additionally, the set cutoff threshold (16 ng/mL) was >90% accurate with an 
AUC of 0.953 (Figure 6D).  Sensitivity and specificity for distinguishing benign 
samples from cancer patients were 84.1% and 84.4%, respectively (Figure 6E), 
while the set cutoff threshold of 80 ng/mL as determined by a 95% confidence 
interval was 83% accurate with an AUC of 0.88 (Figure 6E).   
Levels of uAS were also compared in 11 patients immediately prior to and 
within 3 weeks following initial cytoreductive surgery (Figure 7A); no 
chemotherapy was administered during this interval.  uAS decreased to control 
levels in those patients (# 17, 21, 22 and 42) in which chart review indicated 
successful tumor ablation and to a lesser extent in suboptimally debulked patient 
# 40.  A postoperative increase was observed in patient # 20 who developed 
ascites.  Urinary samples were also collected in patients # 5, 27, 43, 49 and 51 at 
7 and/or 12 months after initial surgery (Figure 7A).  In these 5 patients, uAS was 
indicative of resistant (# 5, 43 and 51) or sensitive (# 27 and 49) disease. These 
data suggest, then, that uAS levels may correlate with surgical debulking and/or 
recurrent EOC and warrant further investigation.         
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Figure 4.  Elevated uAS correlates with recurrent EOC and complements CA125 
measurements.  (A.) uAS was evaluated by lysine-ELISA before and after surgery in 11 patients.  
Samples were examined in duplicate and data expressed as mean ng/mL per patient.  A- 3 
weeks after surgery, B- 7 months after surgery, and C- 12 months after surgery.  (B.) uAS and 
blood levels of CA125 were measured from the same healthy controls and EOC patients (muc, 
mucinous; serous, serous adenocarcinoma; PP, primary peritoneal) prior to initial cytoreductive 
surgery.  uAS data expressed as mean ng/mL per patient and CA125 data expressed as mean 
U/mL per patient.  * False-positive or False-negative  
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Elevated uAS levels complement CA125 values 
 While studies continue to identify EOC biomarkers (132, 133), CA125 
remains the current “gold standard” for EOC detection followed by TVS and 
pelvic examination.  CA125 is useful in the follow-up of EOC patients after 
surgical and chemotherapeutic management but its value in early detection and 
overall management is not ideal due to the test‟s limited sensitivity and specificity 
(27) and to the fact that this malignancy is neither rare nor frequent (115).  While 
nearly 2/3 of patients with clinical disease will have elevated CA125 levels, less 
than 50% of early stage EOC will be detected by CA125.  Therefore, in this initial 
evaluation, we compared uAS to CA125 levels in 12 healthy controls and 23 
cancer patients to address the potential for uAS to serve as a biomarker for EOC 
(Figure 7B).  Elevated uAS (>16ng/mL) was associated with 88% EOC detection, 
correctly identifying 15/17 serous, 3/4 mucinous and 2/2 PP carcinomas in 
cancer patients (Figure 7B).  In contrast, CA125 levels (>35 U/mL) from matched 
samples was associated with only 74% EOC detection, correctly identifying 
13/17, 3/4, and 1/2 of patients with serous, mucinous and PP cancer, 
respectively, as cancer positive (Figure 7B). All healthy controls were correctly 
classified as cancer-negative by uAS (<16 ng/mL) whereas 2/12 healthy controls 
were incorrectly identified as cancer-positive by CA125 (Figure 7B).  In addition, 
PPV and NPV were 09.23 and 0.836, respectively; and 95% confidence intervals 
were 133.5-316.6 ng/mL for uAS and 97.6-285.8 U/mL for CA125.  Lastly, 
statistical analyses revealed a positive Spearman correlation of 0.5431, p ≤ 
0.0007 between uAS and CA125.  Therefore, there is evidence of a statistically 
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significant positive correlation indicative of complementarity between uAS and 
CA125 in the ability to detect ovarian cancer.  Further, EOC could be detected in 
91.3% (21/23) of samples when using the criteria that one or both of these 
biomarkers were elevated.  
 
Discussion 
 
While angiogenesis is an essential biological process for embryonic 
development and normal physiological processes, it is also involved in a number 
of pathologic conditions including chronic inflammation, immunological diseases, 
and cancer (134).  Angiogenesis is regulated by several factors that can either 
promote or inhibit the development of new blood vessels and since EOCs are 
generally highly vascularized tumors our study aimed at the evaluation of 
angioregulators in bodily fluids as potential biomarkers for EOC.   
Investigated angioregulators included VEGF, HGF, ES and AS. VEGF, a 
30-42 kDa homodimer produced by a variety of cell types including cancer cells, 
has emerged as a critical regulator of the angiogenic process by promoting 
endothelial migration, proliferation, protease activity and capillary tube formation 
(53).  VEGF levels in various body fluids are increased during cancer progression 
(72, 121).  HGF is a pleiotropic growth factor that is implicated in the growth and 
spread of some epithelial tumors (124) and is present in benign and malignant 
ovarian tissues, cysts and ascites (122).  A proportion of ovarian tumors also 
express high levels of the HGF receptor, c-Met (135), and this expression may 
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add a selective growth advantage to a narrow subset of differentiated EOCs.  ES 
is a 20-kDa C-terminal fragment of collagen XVIII originally isolated from a 
murine hemangioendothelioma that has been shown to specifically inhibit 
endothelial cell proliferation, angiogenesis and tumor growth (128).  Blood and 
urinary levels of ES have been reported as elevated in vulvar and other 
malignant disease (129-131, 136), but the role of ES in EOC has not yet been 
explored.   
AS is a specific 38kDa internal fragment of plasminogen that inhibits 
angiogenesis by blocking endothelial cell growth via its kringle 1-3 regions (129, 
131, 137).  AS synergizes with ES in inhibiting angiogenesis and EOC growth 
(138) and the two angiostatic molecules may thus be valid targets for anti-
angiogenic therapy in cancer via recombinant viral strategies (134, 139).  AS and 
other plasminogen cleaved products are present in malignant ascites and may 
contribute to the net anti-angiogenic properties of this fluid (73).  In a single 
immunohistochemical study of AS expression in EOC, survival time was longer in 
patients with AS-positive and VEGF-negative tumors than in patients with AS-
negative and VEGF-positive tumors (127).  AS has also been sparingly reported 
as elevated in the urine of leukemic and some solid cancer patients suggesting 
that urinary detection of this angiogenesis inhibitor may provide new diagnostic, 
prognostic and potentially therapeutic tools (129, 131).   
Our study suggests that uAS provides a more sensitive marker than other 
angioregulators.  Specifically, our data indicates significantly elevated uAS 
discriminates EOC from healthy controls and women with benign gynecologic 
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disease.  Further, the most apparent clinical features related to uAS are detection 
of early stage EOC and complementarity with CA125. While the former 
represents an important target group associated with high survival (>95%), the 
latter suggests potentially important diagnostic and prognostic roles for uAS; 
especially when both biomarkers were taken into consideration over 91% of 
ovarian cancer was detected and all normal individuals were identified as 
healthy.   
In future, ELISA or spot assays of combined or dominant urinary proteins 
may be used for diagnostic and prognostic applications.  These assays may be 
used in combination with tests currently utilized to detect EOC at an earlier stage, 
thereby decreasing patient mortality.  After surgery, patients could also be 
evaluated for recurrence by easily monitoring the urine for such proteins.  
Measuring these angiogenic regulators  may also be pursued in other readily 
accessible body fluids such as saliva as done for other diseases (140).  Finally, 
the identification of an EOC-related angiogenic profile may lead to the 
formulation of adjuvant therapies utilizing target-specific anti-angiogenic drugs. 
Validation of AS as a urinary biomarker for the clinical detection may offer 
a non-invasive, convenient, and cost-effective screening and diagnostic tool for 
detection of this most lethal gynecologic malignancy.  This would allow women to 
make better decisions about their health options and potentially reduce the 
mortality associated with this insidious disease. 
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CHAPTER III 
 
EXPRESSION OF SEMAPHORIN 3F AND ITS RECEPTORS IN EPITHELIAL 
OVARIAN CANCER, FALLOPIAN TUBES AND SECONDARY MÜLLERIAN 
TISSUES  
 
Abstract 
 
 While semaphorins and their receptors appear to play a role in tumor 
carcinogenesis, little is known about the role of SEMA3F in EOC development.  
Therefore, we sought to determine the clinical relationship between S3F and its 
receptors, NP-2 and NP-1 with EOC progression.  We analyzed the 
immunohistological expression of SEMA3F, NP-2 and NP-1 in clinical specimens 
of normal ovaries (N), benign cyst adenomas (Cy), well-differentiated 
adenocarcinomas (WD), poorly-differentiated adenocarcinomas (PD), inclusion 
cysts (IC), paraovarian cysts (PC), and fallopian tubes (FT).  Tissue sections 
were evaluated for staining intensity and percentage of immunoreactive epithelia.  
We found that expression of SEMA3F and NP-2 decreased while NP-1 
expression increased with EOC progression.  Interestingly, we also found 
elevated expression of SEMA3F, NP-2, and NP-1 in epithelia of ICs, PCs, and 
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FT.  Our findings indicate that loss or deregulation of semaphorin signaling may 
play an important role in EOC development. 
 
Introduction 
  
 EOC is the most lethal and the second most commonly diagnosed 
gynecological malignancy. It is estimated that in 2009, it will strike over 21,000 
women seventy percent of whom will be first diagnosed at advanced stages and 
will die within five years (141).  In general, EOC is characterized by poor 
prognosis due to lack of early symptoms, which contributes to advanced stage of 
disease at presentation, and by the absence of accurate screening methods to 
detect early stages of the disease.  The origin of this malignancy has been 
traditionally attributed to the OSE.  However, alternative theories to a coelomic 
origin attribute the source of EOC to primary or secondary Müllerian system 
derivatives such as the fimbriated end of the fallopian tube and paraovarian 
vestigial structures, respectively (7, 19, 20).  The Müllerian system theory would 
explain why epithelial ovarian neoplasms present as morphological variants of 
fallopian tube (serous adenocarcinoma), uterus (endometrioid), or endocervix 
(mucinous adenocarcinoma) epithelia without requiring an intermediate 
metaplastic step (19).  Independently of its cell of origin, the pathogenesis of this 
most lethal gynecologic malignancy is, however, not well understood. 
Semaphorins are a large family of transmembrane, secreted, or GPI-
anchored, proteins involved in axon guidance and growth cone collapse through 
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interaction with their receptors, the neuropilins and plexins (82).  There are eight 
classes of semaphorin genes all of which are characterized by a conserved 500 
amino acid, cysteine-rich Sema domain, which mediates binding specificity and is 
necessary for signaling (82). Plexins are transmembrane receptors that form 
complexes with NP transmembrane receptors, which only directly interact with 
SEMA3 members, and mediate signal transduction following binding to a 
semaphorin (87).  Additional biological functions for semaphorins and their 
receptors include regulation of angiogenesis as well as tumor progression and 
metastasis (142, 143). 
With regard to angiogenesis, SEMA3s are of interest since members of 
this class have demonstrated either pro- or anti-tumorigenic functions.  SEMA3s 
are unique in that they directly bind NP homo- or hetero-dimeric receptors and 
are unable to bind directly to plexins with the exception of SEMA3E (85, 86, 144, 
145).  However, signaling is regulated through an oligomeric complex involving a 
NP dimer and one of four type-A plexins (87, 146-148).  Interestingly, NPs also 
function as co-receptors with VEGFRs for VEGF whose over expression 
contributes to tumor growth and metastasis (89).  In addition to VEGF family 
members, NPs also interact with other heparin-dependent growth factors like 
bFGF and HGF (93). Of interest is SEMA3F, a class 3 secreted protein which 
plays a critical role during neural development in both the peripheral and central 
nervous systems through interaction with its high affinity receptor NP-2 and low 
affinity receptor NP-1 (148).  SEMA3F has also been shown to inhibit 
angiogenesis by decreasing blood vessel density and through competition with 
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VEGF for a shared receptor complex (108, 149).  Specifically, SEMA3F induces 
a poorly vascularized, encapsulated, non-metastatic phenotype through 
chemorepulsion of endothelial cells in melanoma (150).  In breast cancer, 
SEMA3F disrupts intercellular contacts of MCF7 breast cancer cells through 
delocalization of E-cadherin and β-catenin (142).  Further, SEMA3F and VEGF 
demonstrate opposing effects for cell attachment and spreading (151), as well as 
migration (152).   
SEMA3F loss or delocalization has been shown to correlate with 
advanced tumor stage in a number of cancers including lung (110); however, a 
correlation between SEMA3F and tumor stage, grade, and histological subtype 
remains to be demonstrated in ovarian cancer.  In order to begin to better 
understand epithelial ovarian carcinogenesis, we sought to determine the clinical 
relationship between SEMA3F and EOC progression.  Therefore, we analyzed 
the immunohistochemical expression of SEMA3F and its two receptors NP-1 and 
NP-2 in clinical specimens.   
 
Materials and Methods 
 
Tissue Specimens 
With institutional approval, 44 specimens were retrieved from the tissue 
bank at H. Lee Moffitt Cancer Center and Research Institute.  Serial 4-5μm 
sections were hematoxylin and eosin stained and classified according to FIGO 
criteria (International Federation of Gynecology and Obstetrics) as normal 
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ovaries (N, n = 12), benign serous cyst adenomas (Cy, n = 10), well differentiated 
serous cystadenocarcinomas (WD, n = 4), poorly differentiated serous 
cystadenocarcinomas (PD, n = 6) and fallopian tubes (FT, n = 4).  Three of 4 WD 
carcinomas were late stage (III-IV) whereas all PD specimens were of late stage.  
We also evaluated epithelia of inclusion cysts (IC, n = 6) and paraovarian cysts 
(PC, n = 2) from patients with otherwise normal ovaries and fallopian tubes. 
 
Immunohistochemistry 
Immunohistochemical staining was performed on serial paraffin-
embedded sections by the horseradish peroxidase (HRP) conjugated system 
using a Dako Autostainer Plus (Dako North America, Inc., Carpinteria, CA).  
Microwave antigen retrieval was achieved using 10x Antigen Retrieval AR-10 
(Tris) (BioGenex, San Ramon, CA) or 10mM citrate buffer for 17 minutes.  
Endogenous peroxidase was blocked with 3% aqueous hydrogen peroxide.   
Sections were rinsed twice with deionized water, washed in Tris buffered saline 
(TBS)/Tween for 5 minutes and  immunostained on the Dako Autostainer  with 
the following: rabbit anti-SEMA3F polyclonal antibody (Chemicon, Billerica, MA) 
at 1:50 for 1 hour at room temperature, rabbit anti-neuropilin-1 polyclonal 
antibody (ECM Biosciences, Versailles, KY) at 1:200 overnight at 4°C, and the 
mouse anti-NP-2 monoclonal antibody (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA) at 1:75 for 1 hour at room temperature.  Secondary antibodies for 
SEMA3F and NP-2 were Vector Elite ABC Peroxidase, using rabbit IgG and 
mouse IgG, respectively; DAB was the chromogen.  The secondary antibody for 
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NP-1 was EnVision+ Peroxidase polymer.  Sections were counterstained with 
modified Mayer‟s hematoxylin.  
Immunostaining of SEMA3F, NP-1, and NP-2 was evaluated by two 
independent observers (SVN and CD) and scored based on staining intensity 
from 1 to 3 (0, negative; 1, weak; 2, moderate; and 3, strong) and percent of 
positive epithelial cells (1, 1-10%; 2, 10-50%; and 3, >50%).  Cellular localization 
of SEMA3F, NP-1, and NP-2 was also assessed.   To confirm the specificity of 
the antibodies, non-immune rabbit IgG and goat IgG were used as negative 
controls in place of primary antibodies for tissue specimens.  Specificity was 
further confirmed by Western blot analyses of cell lysates and visualization of the 
corresponding protein bands at the appropriate molecular weights for the 
respective antibodies (data not shown).  
 
Statistical analyses  
Statistical analysis of staining for SEMA3F, NP-1, and NP-2 among clinical 
samples was analyzed by Spearman rank correlation and Fisher exact test for 
differences in staining intensity and histological type.  ANOVA analyses were 
performed to determine significant differences in percentage of positively stained 
epithelia between N, N combined with FT, Cy, and cancer (WD combined with 
PD) groups.  Spearman and Fisher exact tests were performed with SAS version 
9.2 (SAS Institute, Cary, NC) and ANOVA tests were performed with Microsoft 
Excel (Microsoft, Redmond, WA).  P-values < 0.5 were considered statistically 
significant. 
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Results 
 
SEMA3F expression decreases with epithelial ovarian cancer progression.  
When all histological subtypes were considered, the expression level of 
SEMA3F in epithelial cells was relatively weak and decreased with tumor 
progression.  We found a significant inverse correlation between SEMA3F 
staining intensity and histology where 83.3% (10/12) of N, 80% (8/10) of Cy, and 
75% (3/4) of WD specimens expressed weak SEMA3F staining, whereas the 
majority of PD specimens, 67% (4/6), completely lacked SEMA3F expression 
(Figures 8-9) (p<0.0001).  No differences were observed as function of stage.  
Interestingly, when we evaluated the percentage of positive epithelia in the 
sections expressing SEMA3F a significantly higher percentage of normal OSE 
was immunoreactive compared to Cy (p<0.001) and cancer (p<0.001) (Table 3).  
The staining pattern throughout the tissue sections was predominantly 
cytoplasmic though a small portion (<20%) of epithelial cells demonstrated basal 
membranous staining pattern in normal, benign, and well differentiated 
carcinomas (Figure 8).   
Stromal cells of all histological groups did not express SEMA3F with the 
exception of endothelial cells that, together with positive control placental tissues, 
expressed SEMA3F in a cytoplasmic and membranous localization (Figure 8, 
arrow), thus providing in our cohort an internal positive control for SEMA3F 
expression.  Immunostaining was not observed in negative control samples 
(Figure 8, inset). 
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Table 3.  Epithelial expression of SEMA3F and NP-2 decreases while NP-1 
increases with ovarian epithelial tumor progression. 
 
  SEMA3F NP-2 NP-1 
N 67.5 ± 1.6 71.4 ± 3.0 80.5 ± 1.4 
Cy 42.9 ± 2.3 
* p ≤ 0.001 ◊ p ≤ 0.05 
 
48.8 ± 2.1 
* p ≤ 0.001 ◊ p ≤ 
0.001 
 
86.5 ± 1.8 
* p ≤ 0.001 ◊ p ≤ 
0.001 
 
WD 21.6 ± 3.9 
** p ≤ 0.001 ○ p ≤ 
0.05 
 
19.2 ± 4.4 
** p ≤ 0.001 ○ p ≤ 
0.001 
 
100 
** p ≤ 0.001 ○ p ≤ 
0.001 
 
PD 29.5 ± 1.5 
** p ≤ 0.001 ○ p ≤ 
0.05 
 
17.1 ± 2.3 
** p ≤ 0.001 ○ p ≤ 
0.001 
 
100 
** p ≤ 0.001 ○ p ≤ 
0.001 
 
IC 100 100 100 
PC 100 85.7 ± 4.5 82.5 ± 2 
FT 100 72.2 ± 3.6 100 
 
Note: * - N vs Cy   ** - N vs WD+PD    ◊ - N + FT vs Cy   ○ - N + FT vs WD+PD 
Abbreviations:  normal (N), serous cystadenoma (Cy), well-differentiated serous adenocarcinoma 
(WD), poorly differentiated serous adenocarcinoma (PD), inclusion cyst (IC), paraovarian cyst 
(PC) and fallopian tube (FT) 
Data represent the average percent of positive epithelium expressing SEMA3F, NP-2, and NP-1 
± SE.   
57 
 
 
Figure 8.  SEMA3F expression decreases while NP-1 increases with epithelial ovarian 
cancer progression.  Representative illustrations of immunohistochemical staining of normal 
(N), serous cystadenoma (Cy), well-differentiated  (WD) and poorly differentiated (PD) serous 
adenocarcinomas) for SEMA3F, NP-2, and NP-1.  Placental tissue was used for positive control 
(C) and arrow indicates expression of SEMA3F by endothelial cells.  Primary antibodies were 
replaced with non-immune serum in negative control sections (inset).  Original magnification: 
400x.   
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Figure 9.  Graphical depiction of SEMA3F, NP-2, and NP-1 expression with epithelial 
ovarian cancer progression.  Immunohistochemically stained sections of normal (N), serous 
cyst adenomas (Cy), well-differentiated (WD) and poorly differentiated (PD) serous 
adenocarcinomas were evaluated for expression of SEMA3F, NP-2 and NP-1 and scored as 
negative (Neg), weak (W), moderate (M), or strong (S) as described in Materials and Methods. 
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NP-2 expression decreases with epithelial ovarian cancer progression. 
NP-2 was generally weakly expressed in all histological groups but the 
proportion of positive epithelial cells significantly decreased with tumor 
progression.  The expression of NP-2 in 33% (4/12), 20% (2/10), 50% (2/4), 33% 
(2/6) of N, Cy, WD, and PD was generally weak (Figures 8-9) and with no 
significant statistical difference.  In contrast to normal ovaries where 71.4% of 
OSE positively expressed NP-2, the percentage of positive epithelia was 
significantly lower in Cy, WD and PD where only 48.8%, 19.2%, and 17.1% were 
positive, respectively (p<0.001) (Table 3).  The overall staining pattern was 
cytoplasmic and membranous in all histological groups (Figure 8).  Interestingly, 
most cells expressing NP-2 in the examined WD carcinomas were localized in 
highly distinctive clusters within the tissue specimens of early stage compared to 
late stage (Figure 10).  
In contrast to epithelial cells, over 90% of stromal cells in normal ovaries 
strongly expressed NP-2 (Figure 8).  Similar to normal tissue, stromal cells in Cy, 
WD, and PD tissues expressed NP-2, however, the level of expression was 
moderate (Figure 8). Like SEMA3F, all endothelial cells within the stroma and 
positive control placental tissues expressed NP-2 immunostaining.  
60 
 
 
 
Figure 10.  NP-2 expression occurs in distinct clusters of tumor cells.  Representative 
illustration of NP-2 expression in well-differentiated serous adenocarcinoma (WD).  Original 
magnification 100x and inset 200x. 
 
 
 
NP-1 expression increases with epithelial ovarian cancer progression.  
In contrast to SEMA3F and NP-2, the overall expression of NP-1 
increased significantly with tumor progression.  Most (93.8%, 30/32) of the 
tissues examined expressed NP-1 (Figure 9).  The overall staining intensity of 
NP-1 in N and Cy sections ranged from weak, 58% (7/12) and 60% (6/10), to 
moderate, 25% (3/12) and 30% (3/10), respectively (Figures 8-9, Table 3).  In 
contrast, the vast majority of cancerous tissues, 75% (3/4) of WD and 83% (5/6) 
of PD samples, strongly expressed NP-1 (Figures 8-9); however, no differences 
were observed as function of stage.  The percentage of positive epithelial cells 
also significantly increased as 80.5%, 86.5%, and 100% of epithelia were 
positive for NP-1 in N, Cy and cancer tissues, respectively, (Table 3). 
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Most stromal cells in N and Cy tissues expressed NP-1, although the 
staining intensity was less than for NP-2. Stromal staining was less in cancerous 
than in N and Cy tissues (not shown). 
 
SEMA3F, NP-2, and NP-1 expression is elevated in inclusion cysts, 
paraovarian cysts, and fallopian tube epithelium.   
Given the uncertain cellular origin of EOC, coelomic versus extrauterine 
Müllerian, we also evaluated the immunohistochemical expression of SEMA3F, 
NP-2, and NP-1 in ICs, PCs, and FT tissues.  We found an elevated staining 
intensity and percentage of epithelial cells expressing SEMA3F and its receptors 
in ICs, PCs, and FT sections when compared to normal ovarian and cancerous 
tissues (Figures 11-12, Table 3).  In contrast to WD and PD tissues where only 
21.6% and 29.5% of the epithelium were positive, 100% of the epithelium lining 
the ICs expressed S3F (Table 3).  All PCs and FT epithelia expressed SEMA3F 
either moderately or strongly (Figures 11-12, Table 3). Similar to the normal 
ovary, only endothelial cells, but no other surrounding stromal cells expressed 
SEMA3F. 
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Figure 11.  SEMA3F expression is elevated in inclusion cysts, paraovarian cysts, and 
fallopian tubes. Representative illustrations of immunohistochemical staining of normal ovary 
(N), inclusion cyst (IC), paraovarian cyst (PC), and  fallopian tube (FT) for SEMA3F, NP-2, and 
NP-1.  Original magnification 400x. 
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Figure 12.  Graphical depiction of SEMA3F, NP-2, and NP-1 expression in inclusion cysts, 
paraovarian cysts, and fallopian tubes compared to normal ovaries.  Immunohistochemically 
stained sections of normal ovary (N), inclusion cysts (IC), paraovarian cysts (PC) and fallopian 
tubes (FT) were evaluated for staining intensity and designated as negative, weak, moderate, or 
strong following staining with antibodies directed against SEMA3F, NP-2, and NP-1. 
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NP-2 expression but not intensity was comparable to SEMA3F in epithelial 
cells of ICs and PCs (Figures 11-12, Table 3). In contrast to WD and PD where 
only 19.2% and 17.1% of the epithelial cells were positive for NP-2, respectively, 
100%, 85.7%, and 72.2% of the epithelia lining ICs, PCs, and FT, respectively, 
were positive (Table 3).  In contrast to the strongly staining stromal cells of the 
normal ovary, weak NP-2 stromal staining was found in FT and PCs.  All 
endothelial cells were strongly immunoreactive for NP-2. 
Epithelial expression of NP-1 in ICs, PCs, and FT was universal (Table 3) 
and similar to cancerous tissues; in contrast to normal ovaries, 50%, 50%, and 
25%, respectively of IC, PC, and FT epithelia exhibited strong NP-1 staining 
(Figures 11-12).  Similar to NP-2, stromal cells displayed negative to weak NP-1 
expression while all endothelial cells were positive. 
 
Discussion 
 
 Loss or delocalization of SEMA3F has been shown to correlate with 
advanced tumor stage in lung cancer (110, 153).  In this study, we sought to 
determine the clinical relationship between SEMA3F and epithelial ovarian 
cancer progression.  Overall, we observed a significant decrease in both intensity 
and frequency of SEMA3F staining with EOC progression.  Although, tumors of 
high grade and advanced stage expressed the least amount of SEMA3F, tumor 
grade was the only parameter that indicated a significant relationship between 
SEMA3F expression and EOC progression in this initial cohort of patients.  
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Levels of SEMA3A have also been reported to be significantly reduced in 
advanced EOC and metastases (111).  Taken together, these findings suggest 
that the loss or deregulation of semaphorin signaling may play an important role 
in EOC progression and support a tumor suppressor function for this molecule 
(108). 
In contrast, the SEMA3F receptors NP-2 and NP-1 have been reported to 
be over-expressed in some cancers, including EOC (111, 153).  In agreement 
with previous reports, we found that the staining intensity and percentage of 
epithelium expressing NP-1 significantly increased with EOC progression and 
was predominantly cytoplasmic.  However, we found that NP-2 expression 
decreased with EOC progression.  Differences in these results compared to other 
reported findings may reflect methodological differences in sample preparation, 
scoring of immunostaining, and case distribution.  Interestingly, we observed 
prominent staining of NP-2 in isolated, but highly distinct clusters of tumor cells in 
early stage and low grade (WD) ovarian cancer tissues similar to that described 
by Brambilla et al. (110) in non-small cell lung cancer.  These observations, in 
addition to the cytoplasmic localization of receptors we observed and previously 
reported in both lung and ovarian cancers (111, 153), may further support a role 
for a SEMA3F-NP pathway in epithelial cell adhesion and/or migration. 
Carcinomas arising from the ovary, FT, and peritoneum have histological 
and clinical similarities (20).  Histological similarities with epithelia lining ICs, 
PCs, and FT have also been documented and explained on the basis of common 
coelomic or Müllerian system origin (19, 20).  In the present study, while there 
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was only weak expression of SEMA3F and NP-2 in EOC, OSE, and IC there was 
strong expression of NP-1 in FT, PC, and EOC.  This shared phenotype indirectly 
supports a common Müllerian origin for epithelial ovarian cancer.  Given the 
slightly younger pre-menopausal age of normal individuals compared to the peri- 
to post-menopausal age of benign and ovarian cancer patients, a potential 
contribution of menopausal status on SEMA3F expression cannot be ruled out.  
Although in this initial series, there was no noticeable difference in SEMA3F 
expression among normal specimens, additional studies are needed to further 
evaluate independency from hormonal status.  Interestingly, Joseph et al. 
recently reported on regulation of SEMA3B and SEMA3F by gonadotropins (FSH 
and LH) and estradiol in ovarian cancer cell lines (154).  SEMA3F expression 
was enhanced by estradiol only indicating that SEMA3F was less sensitive to 
hormone treatment compared to SEMA3B, which was stimulated by FSH and LH 
in addition to estradiol (154).  Therefore, these studies suggest that hormonal 
regulation of SEMA3F may play a role in the ovary and EOC, certainly, additional 
studies are necessary to further elucidate the mechanism(s) involved in hormonal 
regulation of SEMA3F.       
In conclusion, our data suggests that the SEMA3F-NP pathway may be 
deregulated in EOC pathogenesis.  Further investigation of SEMA3F and its 
receptors in epithelial ovarian cancer is warranted to delineate the molecular 
pathway(s) by which such deregulation may promote tumor progression and, if 
so, provide novel molecular targets for therapeutic intervention. 
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CHAPTER IV 
 
SEMAPHORIN 3F DYSFUNCTION INDUCES TELOMERASE ACTIVITY IN 
OVARIAN CANCER CELLS 
 
Abstract 
 SEMA3F is a secreted with potent angiostatic activity and although studies 
have indicated that loss expression of SEMA3F correlates with cancer 
progression, including EOC, less is known about SEMA3F regulation and/or 
dysregulation.  Since studies of the nervous system suggest that calcium 
influences SEMA3 signaling and since cyclic adenosine monophosphate (cAMP) 
response element binding protein (CREB) is activated by calcium, we 
investigated the potential for calcium and CREB to regulate SEMA3F in OSE and 
ovarian cancer cells.  In the present study, we demonstrated that both calcium 
and CREB suppress SEMA3F expression and CREB could specifically target the 
-4810 to -4418 region of the SEMA3F promoter.  Since we have previously 
demonstrated that VEGF can target specific Sp1 sites within the hTERT 
promoter to stimulate telomerase activity and given the antagonistic relationship 
between SEMA3F and VEGF, we also evaluated the relationship between 
SEMA3F and telomerase using semi-quantitative RT-PCR, Western blot 
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analyses, and PCR-ELISA.  We found a significant inverse relationship, in 
addition SEMA3F could regulate telomerase activity by targeting regions of the 
hTERT promoter, alternative to the VEGF responsive regions.  These results 
demonstrate that calcium and CREB negatively regulate SEMA3F expression in 
OSE and ovarian cancer cells.  SEMA3F loss is associated with an increase in 
telomerase activity.  Moreover, ectopic expression of SEMA3F could mediate 
suppression of telomerase activity.  Together, these data provide evidence that 
calcium and CREB can negatively regulate SEMA3F, in addition telomerase 
appears to be a novel molecular target of SEMA3F.       
 
Introduction 
 
 Semaphorins are a large family of secreted, transmembrane, or GPI-
anchored proteins that play a critical role as axon guidance molecules in the 
developing nervous system.  However, they are also widely expressed outside 
the nervous system and influence a variety of cellular mechanisms including 
migration, proliferation, cytoskeleton rearrangement, angiogenesis  and cancer 
progression (80, 103, 155-157).  Secreted SEMA3s (158), which are 
distinguished by the presence of a C-terminal basic domain and function in a 
paracrine manner through a NP/plexin holoreceptor complex (82).  Unlike other 
semaphorin family members, SEMA3s directly bind NP receptors with the 
exception of SEMA3E, however similar to other semaphorin family members the 
plexin receptor initiates signal transduction (82).  
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SEMA3F was originally isolated from a recurrent homozygous deletion in 
the 3p21.3 chromosomal region in small-cell lung cancer (159-161), a region also 
frequently lost in ovarian cancer (107).  Normally SEMA3F functions to suppress 
tumor formation and/or progression.  More specifically, exogenous SEMA3F 
inhibits tumor formation in several xenograft models (108, 149, 150).  In addition, 
SEMA3F expression is associated with reduced blood vessel density and a 
nonmetastatic tumor phenotype, suggestive of angiostatic activity (150).  The 
angiostatic activity of SEMA3F is due, in part, to competition of overlapping NP 
binding sites with the angiogenic factor VEGF (104).  Alternatively, re-expression 
of SEMA3F in H157 lung cancer cells negatively affects VEGF mRNA expression 
due to decreased signal transducer and activator of transcription 3 (STAT3) 
phosphorylation and loss of Akt-dependent hypoxia-induced factor 1α (HIF-1α) 
protein (109, 112).   
As seen in lung cancer (153), we and others have previously 
demonstrated decreased SEMA3F expression with EOC progression (154, 162), 
however, the positive and negative mechanisms regulating SEMA3F expression 
remain unclear.  To date, DNA methylation correlates with suppression of 
SEMA3F expression (106).  Similarly, Clarhaut et al. reported that the zinc finger 
transcription factor and key regulator in epithelial-mesenchymal transition, ZEB-
1, down-regulates SEMA3F by targeting a specific E-box sites located in the CpG 
island of the SEMA3F promoter (112).  Alternatively, chromatin remodeling by 
histone deacetylase inhibition contributes to SEMA3F activation (106).  Recently, 
Joseph et al. demonstrated reproductive hormonal regulation of SEMA3F and 
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SEMA3B in ovarian cancer cells, such that, FSH, LH and estradiol stimulated 
SEMA3B, whereas SEMA3F could only be stimulated by estradiol (154).   
The modulation of growth cone turning by guidance cues, like SEMA3F, is 
facilitated by calcium, an essential signaling molecule (163).  Interestingly, levels 
of calcium fluctuate in preparation for rupture of the ovarian follicle and changes 
in calcium can stimulate damaged OSE to proliferate (164).  Moreover, inhibition 
of calcium influx reportedly results in inhibition of ovarian cancer cell proliferation, 
invasion, and angiogenesis (165).  Conversely, hormonal stimulation of SEMA3B 
and SEMA3F blocks invasion and angiogenesis in ovarian cancer cells (154).  
Since loss of SEMA3F correlates with EOC progression and given the effects of 
calcium on SEMA3F in the nervous system and OSE in the ovary, calcium could 
potentially regulate SEMA3F in OSE and ovarian cancer cells.  
In the present study, we investigated mechanisms that positively and 
negatively regulate SEMA3F and how loss may be related to tumor progression.  
We found that calcium suppressed SEMA3F expression in both OSE and ovarian 
cancer cell lines.  We also identified the basic/leucine zipper (bZIP) transcription 
factor, CREB, as a novel SEMA3F transcriptional repressor, while two GC boxes 
are important for transcriptional activation of SEMA3F.  Additionally we found, an 
inverse relationship between SEMA3F expression and telomerase activity such 
that, SEMA3F appears to suppress telomerase in a transcription-dependent 
manner.  Consequences of decreased SEMA3F thus, involve mechanisms that 
promote cancer progression through induction of telomerase activity. 
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Methods and Materials 
 
Cell lines and culture 
A panel of ovarian carcinoma cell lines, including A2780s, A2780cp, C-13, 
CaOV3, ES-2, OV90, OV432, OV433, OV2008, OVCAR3, OVCAR5, PA-I, 
SW626, TOV21G and TOV112D cell lines, and SV40 large-T-antigen-
immortalized ovarian surface epithelial (IOSE) cell lines, including familial history 
human immortalized ovarian surface epithelial 114 (FHIOSE 114), FHIOSE 117, 
FHIOSE 118, immortalized Moffitt Cancer Center 3 (IMCC 3), and IMCC 5 were 
used in this study (166).  Cells were maintained in Medium 199/MDCB 105 (1:1) 
(Sigma, St. Louis, MO) supplemented with 5% fetal bovine serum (FBS) 
(Hyclone, Logan, UT) and 10μg/mL gentamicin (GIBCO BRL, Grand Island, NY) 
in a humidified 5% CO2/95% air atmosphere.   
 
Treatment with SEMA3F, VEGF, CBO-P11, calcium, BAPTA and metal ions 
Two million IOSE and ovarian cancer cells were treated with recombinant 
SEMA3F (0.212µg/mL or 0.424µg/mL) (a generous gift from Dr. Klagsbrun), 
VEGF (50ng/mL) dissolved in BSA (Biosource, Camarillo, CA) and/or 1.3µM 
VEGF receptor inhibitor, CBO-P11, dissolved in Milli-Q water (Calbiochem, La 
Jolla, CA).  Cultures were harvested at 24 hours and assayed for telomerase 
activity. 
In order to determine the role of calcium in SEMA3F regulation, three 
million IOSE and ovarian cancer cells were treated ± 10 mM CaCl2 or ± 1,2-bis(2-
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aminophenoxy)ethane-N,N,N‟,N‟-tetraacetic acid (BAPTA, Sigma-Aldrich, St. 
Louis, MO), a calcium chelator (167),.  Cells were also treated with additional 
divalent cations in the form of chlorine salts.  The salts used were ZnCl2 (100µM, 
1mM), MgCl2 (10mM), CuCl2 (10µM, 100µM), and CsCl2 (1mM) (Sigma-Aldrich, 
St. Louis, MO).  Following suspension of metal salts into medium, pH was 
adjusted to 7.4 then the solution was filtered using a 0.2-um syringe filter and 
added to cells in culture.  Cells were harvested at 24 hours and assessed for 
SEMA3F expression. 
 
Transient transfection and small interfering RNA transfection 
 Two million IOSE and ovarian cancer cell lines were transiently 
transfected using Program X-005 and Kit V on the Nucleofector device 
(Amaxa/Lonza, Walkersville, MD) with pSecTag (Invitrogen, Carlsbad, CA), 
pSecTag-S3F (generous gift from Dr. Tessier-Levigne) which encodes for the 
long splice form of SEMA3F, GFP (Amaxa/Lonza, Walkersville, MD), or pSG3-
CREB (kindly provided by Dr. Cheng) plasmids.  To inhibit expression of 
SEMA3F, two million OSE and ovarian cancer cells were transfected with 
SEMA3F siRNA or non-targeting control siRNA (Qiagen, Valencia, CA).  Cells 
were harvested at 24 or 48 hours post-transfection.  Each transfection was 
performed in three independent experiments.   
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RT-PCR  
To verify expression of SEMA3F and to determine the contribution of 
SEMA3F for transcriptional regulation of human telomerase reverse transcriptase 
(hTERT), semi-quantitative RT-PCR studies were performed, with each 
experiment repeated a minimum of three separate times.  Total RNA was 
collected using TRizol reagent (GIBCO BRL, Grand Island, NY).  One μg total 
RNA, oligo(dT), and reverse transcriptase were used to generate single-strand 
cDNA for each sample.  To ensure there was no DNA contamination, each 
sample for reverse transcription was prepared in duplicate, with one sample 
lacking reverse transcriptase.  The cDNA samples were amplified using Applied 
Biosystems GeneAmp kit (Foster City, CA).  The SEMA3F primers used were 
SEMA3F-Sense (AGCAGACCCAGGACGTGAG) and SEMA3F-Antisense 
(AAGACCATGCGAATATCAGCC) oligonucleotides (Sigma Genosys, The 
Woodlands, TX) and hTERT primers used were hTERT-Sense 
(CGGAAGAGTGTCTGGAGCAA) and hTERT-Antisense 
(GGATGAAGCGGAGTCTGGA) oligonucleotides (Sigma Genosys, The 
Woodlands, TX).  For an internal control β-actin primers were used; actin-Sense 
(GGGAATTCAAAACTGGAACGGTGAAGG) and actin-Antisense 
(GGAAGCTTATCAAAGTCCTCGGCCACA).  PCR for S3F was performed for 35 
cycles of 95°C for 90 s, 55°C for 90 s, and 72°C for 90 s.  β-actin primers were 
added at cycle 18.  PCR for hTERT was performed for 33 cycles of 95°C for 20 s, 
68°C for 40 s, and 72°C for 30 s.  β-actin primers were added at cycle 17.  
Amplified products were then separated by gel electrophoresis, stained with 1x 
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SybrGreen (Cambrex Bioscience Rockland, Inc., Rockland, ME) and analyzed 
with the Kodak EDAS 120 Digital Analysis System.   
 
Telomerase assay 
 To quantitatively detect changes in telomerase activity levels, cell lysates 
were assayed using the telomerase polymerase chain reaction enzyme-linked 
immunosorbant assay (PCR-ELISA) (Roche Applied Science, Indianapolis, IN) 
according to the manufacturer‟s instructions.  Briefly, cells were washed in PBS, 
trypsinized, and spun at 500 x g for 10 min.  Pellets were washed twice in PBS, 
then resuspended in lysis buffer and kept on ice for 30 min, after which the 
lysates were centrifuged at 100,000 x g for 1 hour at 4°C.  Lysates were then 
assayed using the Bio-Rad DC Protein Assay (Bio-Rad, Hercules, CA) for the 
determination of protein concentration, according to the manufacturer‟s 
instructions.  In order to perform the telomerase PCR-ELISA within a linear 
range, cell extracts equivalent to 3μg of protein were used.  Following PCR-
ELISA, telomerase activity was detected using a ELx800 microplate reader (Bio-
Tek Instruments, Winooski, VT) and recorded as absorbance units.   
 
Western blot analysis 
 For Western blot analysis, cell lysates were solubilized in SDS gel loading 
buffer (60 mM Tris base, 2% SDS, 10% glycerol, and 5% b-mercaptoethanol), 
separated via 10% SDS-PAGE and electroblotted onto (0.45µm) PVDF 
membranes (Millipore, Billerica, MA) by wet transfer.  Immunoblotting was 
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performed using antibodies directed against SEMA3F (1:5000, Millipore, Billerica, 
MA), phospho-CREB (1:2500, Cell Signaling, Danvers, MA), total-CREB (1:2500, 
Cell Signaling, Danvers, MA), phospho-Akt ( 1:2500, Cell Signaling, Danvers, 
MA), and total-Akt (1:2500, Cell Signaling, Danvers, MA).  β-actin (1:10,000, 
Sigma-Aldrich, St. Louis, MO) was used as a loading control.  Blots were 
visualized using the ECL Western Blotting Analysis System (Millipore, Billerica, 
MA) according to the manufacturer‟s instructions.  Blots were analyzed and 
scanned with ImageQuant image analysis software (GE Healthcare Bio-Sciences 
Corp., Piscataway, NJ).  Data represent mean relative intensities for S3F, 
phospho-CREB, total-CREB, phospho-Akt, and total-Akt, from three independent 
experiments normalized to the corresponding β-actin levels and expressed as 
mean net intensity. 
 
Luciferase reporter assay 
 To measure promoter activity, 1.5µg SEMA3F luciferase reporter promoter 
constructs pGL3-6310-4013, -5131-3765, -5836-4013; previously described (106, 
112) and pGL3 -4810-4418 and -4810-4013 or hTERT full-length and deletion 
constructs pGL3-1375, -1175, -976, -776, -578, -378, -181; hTERT constructs 
previously described (168), were transfected into IOSE and/or ovarian cancer 
cells using Program X-005 and Kit V on the Nucleofector device (Amaxa/Lonza, 
Walkersville, MD).  In each experiment, the pRL-TK plasmid (100ng), encoding 
Renilla luciferase (Promega, Madison, WI), was co-transfected for normalization 
purposes.  Luminescence was measured 48 hours after transfection using the 
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Dual-Luciferase Reporter Assay System (Promega, Madison, WI).  The pGL3-
basic (promoterless) plasmid was used in each experiment to determine basal 
levels of luciferase.  Reporter activity was normalized by calculating the ratio of 
Firefly/Renilla values and transcriptional activity was expressed as relative 
luciferase activity from triplicate ± S.E. from three independent experiments.   
 
Statistical analysis 
 Samples for telomerase PCR-ELISA were run in triplicate from three 
independent experiments and the data subjected to Student t test analysis for 
determination of statistical significance for S3F suppression of telomerase.  To 
determine the relationship between SEMA3F and telomerase activity we used a 
Spearman correlation coefficient (a nonparametric analog to the Pearson 
correlation coefficient) for statistical analysis. 
 
Results 
 
Calcium suppresses SEMA3F expression in IOSE and ovarian cancer cells 
In agreement with earlier studies (154, 162), SEMA3F levels were lower in 
ovarian cancer versus normal cell lines (>45%).  To ascertain whether calcium 
could mediate SEMA3F expression, we treated IOSE and ovarian cancer cells 
with calcium for 24 hours.  SEMA3F mRNA and protein expression were 
evaluated using semi-quantitative RT-PCR and Western blotting, respectively 
(Figures 13A-B).  Calcium suppressed SEMA3F mRNA expression in IOSE in 
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ovarian cancer cell lines (Figure 13A, top panel).  Likewise, SEMA3F protein 
expression was suppressed in both IOSE and ovarian cancer cells following 
treatment with calcium (Figure13B, top panel).  Densitometric analyses indicated 
calcium suppressed SEMA3F protein expression in IOSE in ovarian cancer cell 
lines by 83% and 67%, respectively (Figure 13B, top panel). 
To verify a role for calcium in SEMA3F inhibition, IOSE and ovarian 
cancer cells were treated with a calcium chelator, BAPTA, for 24 hours and 
assessed for SEMA3F RNA and protein expression.  In agreement with above, 
calcium chelation with BAPTA induced SEMA3F expression by two-fold (Figures 
13A-B, bottom panels).  Cell viability following BAPTA treatment was not 
compromised as determined by trypan blue exclusion (data not shown).  
Additionally, to confirm specificity for calcium to suppress SEMA3F expression, 
FHIOSE 118 cells were treated with various divalent cations at varying 
concentrations for 24 hours (Figure 13C).  Following treatment, samples were 
collected and assessed for SEMA3F protein expression.  Additional metal salts 
examined resulted in SEMA3F expression similar to that of the control samples.   
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Figure 13.  Calcium mediates SEMA3F Suppression in IOSE and Ovarian Cancer Cells.  
Cells were treated with ± 10mM CaCl2 or ± BAPTA and were harvested at 24 hours to measure 
SEMA3F mRNA (A) by semi-quantitative and protein (B) expression by Western blot analyses.  
B-actin was used as a loading control and values are expressed as relative intensity of 
SEMA3F/Actin. (C) To confirm specificity of CaCl2, cells were treated with additional divalent 
cations and measured for SEMA3F protein expression at 24 hours after treatment. 
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Calcium-mediated suppression of SEMA3F is CREB-dependent 
The bZIP transcription factor, CREB, has been implicated in regulating 
OSE survival and proliferation in response to gonadotropins during ovulation 
(169, 170).  Furthermore in vitro and in vivo studies indicate CREB is frequently 
over-expressed in a number of human tumors, including EOC (170).  Since 
CREB activation is dependent on calcium and cAMP (171, 172), we examined 
whether CREB contributes to negative regulation of SEMA3F expression.  IOSE 
and ovarian cancer cells were transiently transfected with a CREB expression 
construct.  CREB expression was verified by Western blot analysis (Figure 14A, 
left panel).  Compared to control cells, ectopic expression of CREB inhibited 
SEMA3F mRNA and protein expression in IOSE and ovarian cancer cells by 
75% and 68%, respectively (Figure 14A).   
 To determine whether CREB represents a novel transcriptional repressor 
of the SEMA3F gene, we performed luciferase reporter assays using [6310-4013] 
SEMA3F promoter and deletion constructs (previously described 16005989, 
19177200) cotransfected ± CREB expression construct, to identify the promoter 
region(s) responsive to CREB.  As shown in Figure 14B, greatest endogenous 
SEMA3F promoter activity occurred in the -4810 to -4418 region.  CREB 
decreased luciferase reporter activity in IOSE cells by 54.2%, targeting the -4810 
to -4418 SEMA3F promoter region (Figure 14B).  
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Figure 14. CREB down-regulates SEMA3F transcription in OSE and ovarian cancer cells. 
(A.) FHIOSE 118 and OV2008 cells were transiently transfected with control or CREB expression 
vector and were harvested at 24 hours to measure SEMA3F mRNA by semi-quantitative RT-PCR 
and protein expression by Western blot analyses.  B-actin was used as a loading control and 
values are expressed as relative intensity of SEMA3F/Actin.  (B.) The SEMA3F luciferase 
reporter constructs were transfected ± CREB expression vector into FHIOSE 118 Firefly 
luciferase activity was measured and normalized to Renilla luciferase activity of the cotransfected 
plasmid pRL-TK for three independent experiments done in triplicate.  (C.) The luciferase reporter 
constructs, with the [-6310-4013] SEMA3F promoter fragment, mutated or not (WT) for each or 
both 3 and 4 of the GC boxes present in the CpG island of this fragment, were transfected into 
FHIOSE 118 cells.  Firefly luciferase activity was measured and normalized to Renilla luciferase 
activity of the cotransfected plasmid pRL-TK for three independent experiments done in triplicate. 
Bars, SE. Statistical analysis was performed with Student‟s t-test: *p<0.05, **p<0.01. 
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SEMA3F promoter region -4810 to -4418 is required for expression in IOSE 
MCF7 breast cancer cells, which express high levels of SEMA3F, have 
promoter activity in a region surrounding the CpG island (106), whereas IOSE 
and ovarian cancer cells that express SEMA3F demonstrate the highest 
luciferase induction within a portion of the CpG island located at -4810 to -4418. 
This region excludes two E-box sites but contains four putative GC-box sites 
(Figure 14B-C).  Therefore, our results suggest that the GC box sites are 
important for positive regulation of SEMA3F in IOSE and ovarian cancer cells.  
To determine the contribution of each GC box site for SEMA3F promoter activity 
we performed additional luciferase reporter assays with [-6310-4013] SEMA3F 
promoter reporter constructs containing all the GC box sites and with promoter 
constructs with mutations in each GC box (GC mut1, GC mut2, GC mut3, GC 
mut4) or combined GC box mutations (GC mut3-4).  Mutations in GC box 2 or 4, 
significantly decreased luciferase activity (54%, 58.6%) in FHIOSE 118 cells 
(Figure 14C, right panel) compared to the wild type sequence -4810-4418 which 
had the highest promoter activity.  Taken together, these results suggest that GC 
box sites 2 and 4 are necessary to induce SEMA3F expression in IOSE and 
ovarian cancer cells, while, a nearby CREB binding site negatively regulates 
SEMA3F. 
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SEMA3F expression is inversely correlated with telomerase in IOSE and 
ovarian cancer cell lines 
In the ovary, telomerase is absent in normal OSE and pre-malignant 
lesions, while tumor cells from both ascites fluid and ovarian carcinomas express 
telomerase activity (173, 174).  Previously we reported that VEGF can induce 
telomerase activity in an ERK1/2-dependent manner in ovarian cancer cells by 
targeting Sp1 binding sites within the proximal 976- to 378- regions of the hTERT 
promoter (175).  Additionally, we have demonstrated that calcium promotes de 
novo telomerase activation in telomerase-negative IOSE cells and elevates 
endogenous activity in telomerase–positive ovarian cancer cell lines (167).   
Using semi-quantitative RT-PCR, we surveyed normal and ovarian cancer 
cell lines for expression of SEMA3F and hTERT, the reverse transcriptase and 
rate limiting component of telomerase.  SEMA3F RNA was strongly expressed in 
IOSE cell lines, while there was a marked decrease in SEMA3F expression in 
ovarian cancer cell lines (Figure 15A).  As expected telomerase-negative IOSE 
cells demonstrated no hTERT expression, whereas all ovarian cancer cell lines 
expressed strongly hTERT mRNA (Figure 15A).  SEMA3F protein expression 
was significantly inversely correlated with telomerase activity, as determined by 
Western blot and PCR-ELISA, respectively (Spearman correlation coefficient, r = 
-0.47, p = 0.035; Figure 15).  
Interestingly, supporting a role for loss of SEMA3F with increasing tumor 
progression and EOC progression (i.e. tumor aggressiveness), we observed that 
parental chemo-sensitive cell lines A2780s, OV2008, and OV432 demonstrated 
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higher SEMA3F expression and lower telomerase activity compared to the 
chemo-resistant daughter cell lines A2780cp, C-13, and OV433 (Figure 15B).    
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Figure 15.  SEMA3F expression is inversely correlated with telomerase in OSE and ovarian 
cancer cells.  (A.) Endogenous hTERT mRNA and SEMA3F protein expression were measured 
in IOSE and ovarian cancer cell lines by semi-quantitative RT-PCR and Western blot, 
respectively. β-actin was used as a loading control. (B.) Graphical depiction of denistometric 
analyses of SEMA3F/ β-actin protein expression and telomerase activity, which was measured by 
PCR-ELISA and values are expressed as relative telomerase activity from triplicate samples. 
(Inset) Western blot indicating higher SEMA3F expression in cancer cells correlates with chemo-
sensitive cell lines versus their respective chemo-resistant daughter cell lines.  
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SEMA3F mediates suppression of telomerase activity in ovarian cancer 
cells 
Given the inverse relationship we found between SEMA3F and 
telomerase, we examined whether SEMA3F could regulate telomerase activity in 
ovarian cancer cells.  Ectopic expression of SEMA3F in OV2008 and C-13 cell 
lines was confirmed by semi-quantitative RT-PCR and Western blot and resulted 
in a marked decrease in hTERT mRNA expression in ovarian cancer cells 
compared to empty vector (Figure 16A).  Similarly, telomerase activity was 
suppressed on average by 35% as determined by PCR-ELISA (Figure 16B).  To 
further validate the specificity of SEMA3F for telomerase suppression we used 
siRNA to inhibit SEMA3F in FHIOSE 118 and OV2008 cell lines (Figure 16C).  
Interestingly, suppression of SEMA3F in OSE resulted in de novo telomerase 
activity (42.6%).  Likewise, telomerase activity increased in ovarian cancer cells 
by 43.5% (Figure 16C). 
 
SEMA3F targets the 378-region and 181-region of the hTERT promoter 
Since, ectopic expression of SEMA3F decreased hTERT mRNA (Figure 
16A, right panel), using full-length and deletion reporter constructs of the hTERT 
promoter, we performed a luciferase reporter assay to identify the promoter 
region(s) responsive to negative regulation by SEMA3F (Figure 16D).  Compared 
to endogenous promoter activity, SEMA3F suppressed luciferase activity in the 
378-bp and 181-bp hTERT promoter regions in OV2008 cells (Figure 16D).  In 
contrast, SEMA3F failed to suppress activity of the full-length, -1175-bp, -976-bp, 
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and -776-bp hTERT promoter regions.  The highest luciferase inhibition was 
achieved using the 181-bp or core hTERT promoter, where we observed a 1.5-
fold decrease (Figure 16D).  These results demonstrate that SEMA3F can 
negatively regulate telomerase by targeting the 378-bp and 181-bp regions of the 
hTERT promoter, in ovarian cancer cells. 
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Figure 16. SEMA3F suppresses telomerase activity in ovarian cancer cells.  OV2008, C-13, 
and other ovarian cancer cells were transiently transfected with control or SEMA3F cDNA and 
were harvested at 24 hours after transfection. Over-expression of SEMA3F was confirmed by (A, 
left panel) semi-quantitative RT-PCR and (A, right panel) Western blot analysis. Values are 
expressed as relative intensity of SEMA3F normalized to β-actin. (B) Transfectants were 
assessed for telomerase activity by PCR-ELISA. Values are expressed as relative telomerase 
activity (Absorbance450nm-Absorbance690nm) of triplicate samples. (C.) FHIOSE 118 and 
OV2008 cells were transiently transfected with control or SEMA3F siRNA and were harvested at 
48 hours after transfection. Silencing of SEMA3F was confirmed by Western blot analysis. Values 
are expressed as relative intensity of SEMA3F normalized to β-actin. Transfectants were 
assessed for telomerase activity by PCR-ELISA. Values are expressed as relative telomerase 
activity (Absorbance450nm-Absorbance690nm) of triplicate samples. (D.) OV2008 cells were 
transfected with full-length and deleted hTERT luciferase reporter constructs ± SEMA3F 
expression vector. Firefly luciferase activity was measured and normalized to Renilla luciferase 
activity of the cotransfected plasmid pRL-TK for three independent experiments done in triplicate. 
Bars, SE. Statistical analysis was performed with Student‟s t-test: *p<0.05, **p<0.01. 
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SEMA3F and VEGF have opposing effects on telomerase activity 
 SEMA3F and VEGF are secreted proteins that share common co-
receptors and activate signaling pathways but with opposing effects (151), 
therefore, SEMA3F may compete with VEGF to suppress telomerase activity.  To 
validate a role for negative regulation of telomerase by SEMA3F and to expand 
upon the antagonistic relationship between SEMA3F and VEGF, we treated 
FHIOSE 118, PA-I and SW626 cells with recombinant SEMA3F ± VEGF or ± 
CBO-P11, a known VEGFR-2 inhibitor.  As expected, treatment with VEGF 
induced telomerase activity in ovarian cancer cells, whereas SEMA3F 
suppressed telomerase activity in a dose-dependent manner (Figure 17).  When 
VEGF was administered with a lower concentration of SEMA3F telomerase 
activity was similar to that of the control; however with a higher concentration, 
SEMA3F was able to overcome competition with VEGF and suppress telomerase 
activity (Figure 17).  Additionally, SEMA3F inhibition of telomerase appears to 
occur, in part, through the VEGFR-2 signaling pathway as indicated by the 
recovery of telomerase activity following treatment with both SEMA3F and CBO-
P11 (Figure 17).  
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Figure 17. SEMA3F and VEGF have opposing effects on telomerase activity.  FHIOSE 118, 
SW626, and PA-I cells were treated with ± VEGF, ± recombinant SEMA3F, ± CBO-P11. Cells 
were harvested at 24 hours after treatment and assessed for telomerase activity by PCR-ELISA. 
Transfectants were assessed for telomerase activity by PCR-ELISA. Values are expressed as 
percent of relative telomerase activity of triplicate samples. 
 
Discussion 
 
Given the correlation between SEMA3F dysregulation and EOC 
progression, it is imperative to elucidate the cellular mechanisms involved in 
SEMA3F regulation in normal physiological conditions and during neoplastic 
transformation in order to exploit the therapeutic potential of SEMA3F.  The 
present study attempted to identify positive and negative regulators of SEMA3F 
in IOSE and ovarian cancer cells.  We found that calcium specifically suppressed 
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both SEMA3F mRNA and protein expression, since treatment with additional 
metal cations had no effect on SEMA3F expression.  Of interest are ongoing 
clinical trials investigating the potential of therapeutic strategies targeting 
inhibition of calcium influx via carboxyamidotriazole (CAI) treatment in ovarian 
cancers (176).  CAI inhibits the influx of calcium into non-excitable cells, like 
endothelial or epithelial cells, and treatment with CAI results in inhibition of 
angiogenesis and signaling pathways that promote adhesion (165, 176).  Taken 
together, these findings suggest SEMA3F may be a clinically useful downstream 
target of CAI therapy in the treatment of EOC.  
Because calcium activates CREB (62, 171, 172), we investigated the 
potential involvement of CREB in calcium-mediated SEMA3F suppression.  We 
identified two possible CREB binding sites in the SEMA3F promoter, one located 
near four putative GC box sites within the CpG island and the second site just 
upstream flanking the CpG island.  We also determined that the -4810 to -4418 
SEMA3F promoter region, which contains a portion of the CpG island, had the 
highest endogenous luciferase activity in IOSE and ovarian cancer cells and was 
most responsive to CREB.   
Differences in effectiveness for CREB to repress SEMA3F promoter 
activity at CREB binding sites within and outside the CpG island may be 
attributed to the presence of multiple transcriptional start sites within the CpG 
island, direct interaction with other transcription factors/basal transcription 
machinery or interference due to methylation outside the CpG island (106).  
Preferential CREB-mediated SEMA3F promoter activity in the CpG island may 
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involve the Sp/KLF family of transcription factors which recognize elements 
within this region and which have been shown to interact with CREB (177).  
Conversely, Sp1 demonstrates a central role in TATA-less promoters and has 
been suggested to be an activator of SEMA3F (106, 178).  Furthermore, our 
results indicate that GC boxes 2 and 4 were necessary and positive regulators 
for SEMA3F promoter activity in IOSE and ovarian cancer cells, so that discrete 
regions of the SEMA3F promoter are important for its expression.  Future studies 
should address the interactions between CREB and other transcription factors or 
a component of the basal transcriptional machinery which may be involved is this 
indirect negative regulation of the SEMA3F gene.  In addition, studies are 
warranted to further elucidate which specific Sp1/KLF family members are 
involved in positive regulation of the SEMA3F promoter via GC box binding sites 
2 and 4. 
Telomerase is a multimeric ribonucleoprotein that adds telomeric repeats 
to chromosomal ends, thereby stabilizing chromosome ends and conferring 
immortality to cells (173, 179).  Since telomerase is expressed in more than 90% 
of human tumors and absent from most normal somatic cells and its expression 
correlates with tumor aggressiveness, telomerase is an attractive target for 
therapeutic intervention.  Epithelial ovarian cancers have a propensity for 
therapeutic failure due to development of drug resistance and changes in 
telomerase may predict therapeutic outcome.  We have previously reported that 
inhibition of telomerase improves chemosensitivity to cisplatin in cisplatin-
resistant ovarian cancer cell lines (180).  In the present study, we found that 
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chemo-resistant cell lines (A2780cp, C-13, OV433) were associated with 
increased telomerase activity compared to their respective parental cell lines 
(A2780s, OV2008, OV432), and subsequently compared to non-tumorigenic 
IOSE cells.  Moreover telomerase activity was not only inversely related to 
SEMA3F expression but was transcriptionally regulated by SEMA3F.  
Interestingly, while we have previously shown VEGF and LPA activate 
telomerase activity by targeting Sp1 sites in the -978 to -378 region of the hTERT 
promoter (175), here we show that SEMA3F suppresses telomerase activity by 
targeting the -378 region and hTERT core promoter region.  These results are 
consistent with earlier studies showing that expression of SEMA3F confers a 
poorly vascularized and non-metastatic phenotype (150) so that together, these 
results suggest that as an alternative to inhibiting angiogenesis, SEMA3F may 
also inhibit tumor progression and survival by negatively targeting telomerase. 
Several transcription factors have been reported as positive and negative 
regulators of hTERT transcription.  Sp1 protein has been shown to specifically 
target the hTERT core promoter and studies indicate that Sp1 sites may 
contribute to basal promoter activity (181-183).  Additionally, mechanisms 
involving E-box binding proteins which are known to heterodimerize with a variety 
of transcription factors with helix-loop-helix domains, such as c-Myc or Mad-
related family members, are implicated in both activation and repression of 
hTERT (184, 185).  Several lines of evidence indicate transcriptional repression 
is associated with the function of a putative telomerase/hTERT repressor gene 
located on the short arm of chromosome 3 (186, 187).  Furthermore, loss of this 
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region as a consequence of deletion or inactivating mutation may occur during 
neoplastic transformation (181, 187).  Interestingly, this 3p region corresponds to 
the known 3p21.3 loci of the SEMA3F gene.  These studies taken together with 
our findings indicating a significant inverse relationship between SEMA3F 
expression and telomerase activity, further implicates SEMA3F may function as a 
repressor of telomerase activity in telomerase-negative normal cells and this 
mechanism becomes defective during the carcinogenic process. 
Lastly, the angiostatic activity of SEMA3F may be due to competition with 
VEGF for common co-receptors. In the present study, SEMA3F abrogated the 
ability of VEGF to enhance telomerase activity.  SEMA3F-mediated telomerase 
occurred, in part, through VEGFR-2, supporting an antagonistic relationship 
between SEMA3F and VEGF due to competition for shared receptors as well as 
promoting opposing effects on a common downstream target.   
SEMA3F acts like a tumor suppressor and dysregulation results in loss of 
expression which can promote tumor progression, angiogenesis and survival.   
To our knowledge, this is the first report of differential SEMA3F regulation in OSE 
and ovarian cancer cells.  We found that the SEMA3F promoter was negatively 
regulated at -4810 to -4418 in a calcium and/or CREB-dependent manner, 
whereas positive regulation was mediated at GC box 2 and 4 within this same 
region.  Additionally, we identified telomerase as a novel molecular target of 
SEMA3F.  Since reactivation of telomerase is critical for cellular immortalization 
and malignant transformation, inhibition of telomerase by SEMA3F demonstrates 
an additional tumor suppressor function and may have clinical utility as adjuvant 
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therapy for enhanced chemosensitization.  Clearly, further studies are warranted 
to exploit the therapeutic potential of these emerging and dynamic cancer 
regulators. 
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CHAPTER V 
 
CONCLUDING REMARKS 
 
 
Although most studies have focused on the role of angiogenic regulators 
for cancer development (37, 42, 53, 65), angiogenesis involves a delicate 
balance between angiostatic and angiogenic regulators and dysregulation of 
angiostatic regulators also contributes to neoplastic transformation, promotes 
tumor progression, and supports chemoresistance.  Therefore, given the overall 
poor outcome of patients with ovarian cancer, filling fundamental gaps in 
knowledge regarding dysregulation of angiostatic regulators is both positively and 
clinically relevant for therapeutic implications.  Novel findings herein define new 
roles for the angiostatic regulators, AS and SEMA3F, in ovarian cancer.   
We report that AS, a potent inhibitor of angiogenesis, may be a useful 
urinary biomarker of high-grade and early stage ovarian carcinomas.  uAS was 
shown to effectively discriminate normal healthy individuals from women with a 
broad range of benign gynecological pathologies, as well as ovarian cancer 
patients.  However, given that several genetic insults are required for malignant 
transformation of OSE into neoplastic cells and since so many environmental 
variables influence the effectiveness of a screening method for ovarian cancer, 
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the possibility of a single biomarker to detect ovarian cancer seems unlikely.  
Recall, a recently proposed pathway which postulates that components of the 
Müllerian system, including the fallopian tube, may be the source of high-grade 
serous epithelial ovarian cancer rather than, or in addition to, the more 
traditionally accepted OSE (19, 20).  This alternative cell of origin has been 
linked to the „p53 signature‟, which characterizes serous tubal intraepithelial 
carcinoma (STIC) and high-grade serous histological subtypes (26).  Similarly, 
the over-expression of high-mobility group AT-hook 2 (HMGA2) occurs in 70-
80% of high-grade serous ovarian carcinomas and STIC and may represent an 
additional biomarker candidate (188).  Therefore, establishing an association of 
high-grade serous carcinoma growth with increased production of p53, HMGA2 
and/or other HMG family members, may identify additional ovarian cancer 
biomarkers in urine as well as other readily available bodily fluids such as saliva 
as done for other diseases (140, 188, 189).    
Consequently, the future of early ovarian cancer detection is likely reliant 
upon the development of a panel of biomarkers, possibly including uAS, that 
collectively complement one another and meet the requirements for sensitivity, 
without compromising specificity.  Such a sophisticated panel of biomarkers in 
conjunction with CA125, could then be used to augment imaging technologies 
and provide a viable two-step approach to screening.  Certainly, improvements in 
early detection of ovarian cancer will reduce the mortality associated with this 
insidious disease.  
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This work also established a clinical and molecular relationship between 
loss of SEMAF expression with EOC progression and in agreement with previous 
studies suggesting a tumor suppressor-like role for SEMA3F (108, 149, 150, 
159).  In agreement with studies indicating calcium regulates SEMA3s in the 
nervous system, we found that SEMA3F was negatively regulated in a 
calcium/CREB-dependent manner in ovarian cancer cells while specific GC 
regions in the SEMA3F promoter are essential for SEMA3F expression in our 
ovarian model system. 
In an attempt to expand upon the antagonistic relationship between 
SEMA3F and VEGF, we found an inverse relationship between SEMA3F 
expression and telomerase activity in IOSE and ovarian cancer cell lines so that, 
this is the first report to identify telomerase as a novel molecular target of 
SEMA3F.  Consequently, loss of SEMA3F not only alleviates competition with 
VEGF which promotes angiogenesis, but also induces telomerase activity which 
confers immortality, tumor aggressiveness, and chemosensitivity.  These studies, 
then, further support the antagonistic relationship between SEMA3F and VEGF 
such that activation of common co-receptors may activate different signaling 
pathways which results in opposing effects on a common downstream molecular 
target (Figure 18).  Future studies are warranted to delineate the mechanisms 
contributing to SEMA3F function and dysregulation in ovarian cancer especially 
as it may pertain to tumor angiogenesis but also with regards to normal 
physiological ovarian processes. 
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Figure 18. Schematic of proposed SEMA3F signaling pathway.  In this schematic 
representation of the antagonistic relationship between SEMA3F and VEGF, we illustrate our 
findings of an opposing effect on a common downstream molecular target, telomerase.  We found 
that SEMA3F uses contrasting signaling pathways compared to VEGF.  Additionally, SEMA3F 
could transcriptionally target specific regions of the hTERT promoter alternative to regions 
targeted by VEGF.  
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Lastly, AS is generated by cancer-mediated proteolysis of plasminogen 
and this is supported by reports identifying additional plasminogen cleavage 
products which demonstrate different degrees of angiostatic potency (75-77).  
Similar to AS, several lines of evidence implicate that regulation of SEMA3s, 
including SEMA3F, also involve proteolytic processing by pro-protein 
convertases, which are a family of calcium-dependent serine endopeptidases 
(190-192).  These enzymes cleave substrates like hormones, growth factors, or 
neuropeptides, at specific consensus sequences to facilitate maturation from an 
inactive precursor form to biologically active peptides (190).  Interestingly, all 
SEMA3s contain a conserved RXRR sequence in the C-terminal region, which is 
the major recognition site of the best studied pro-protein convertase, furin (190).  
Most recently it has been observed that furin processing of SEMA3F can affect 
its angiostatic potency (191).  Likewise, furin-like pro-protein convertases 
reportedly target SEMA3B and render it inactivate (Varshavsky 18757406).   
Furin has been associated with enhanced tumor invasiveness and 
metastasis since many substrates it activates are cancer-associated proteins 
(193).  Overall, proteolytic processing by furin and other pro-protein convertases 
can either activate or inactivate SEMA3 signaling (191).  Taken our findings that 
calcium suppressed SEMA3F and given that furin is calcium dependent, in our 
ovarian model system proteolytic processing may be an important mechanism 
involved in SEMA3F regulation.  Since elevated levels of proteases have been 
linked to the malignant phenotype in a wide variety of tumors, including serous 
epithelial carcinoma of the ovary (125), future studies investigating dysregulation 
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of angioregulators, including the interrelationships between AS and SEMA3F, 
may provide clinically important information about the consequences of aberrant 
expression of enzymes and proteins involved in proteolytic cleavage.   
In summary, research focused on angiostatic regulators, such as AS and 
SEMA3F, may not only benefit ovarian cancer patients, but may also have 
implications for other cancers.  By elucidating the mechanism(s) responsible for 
dysregulation of SEMA3F, it may be possible to develop a therapeutic 
intervention that would not only disturb the vasculature by acting as a VEGF 
competitor but, by targeting telomerase positive cells, could act specifically on 
tumor cells.  Likewise, AS not only has therapeutic potential but has promise as a 
biomarker for early detection of ovarian cancer.  Therefore, a broader 
understanding of the wider roles of angiostatic regulators, as well as delineating 
the molecular mechanisms contributing to dysregulation of angiostatic regulators 
can provide insight into the etiology, clinical presentation and treatment of 
ovarian cancer.  This may eventually allow women more choices for treatment 
and hopefully, reduce the mortality associated with this insidious disease.  
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